

Managing Growth of a Non-Profit Healthcare Supply Chain in Haiti

by

Christine L. Heberley


B.S. Naval Architecture and Marine Engineering
Webb Institute, 2002

and

Matthew F. Hoover

M.P.P. International Security and Public Policy
University of Maryland, 2007

B.S. Economics
Duke University, 2002



ARCHIVES

Submitted to the Engineering Systems Division in Partial Fulfillment of the
Requirements for the Degree of

Master of Engineering in Logistics

at the

Massachusetts Institute of Technology

June 2010

© 2010

Christine Heberley and Matthew Hoover
All rights reserved.

The author hereby grants to MIT permission to reproduce and to distribute publicly paper and electronic
copies of this document in whole or in part.

Signature of Authors: *Ch*
Master of Engineering in Logistics Program, Engineering Systems Division
May 7, 2010

Certified by: *[Signature]*
Dr. Jarrod Goentzel
Executive Director, Masters of Engineering in Logistics Program
Thesis Supervisor

Accepted by:
Prof. Yossi Sheffi
Professor, Engineering Systems Division
Professor, Civil and Environmental Engineering Department
Director, Center for Transportation and Logistics
Director, Engineering Systems Division

Managing Growth of a Non-Profit Healthcare Supply Chain in Haiti

by

Christine L. Heberley

and

Matthew F. Hoover

Submitted to the Engineering Systems Division
on May 7th, 2010 in Partial Fulfillment of the
Requirements for the Degree of Master of Engineering in
Logistics

Abstract

Partners in Health's (PIH) supply chain in Haiti has become strained over the past five years due to the organization's rapid growth. Under the current system, the majority of PIH's products are obtained through an annually placed order. All goods from this order are stored at the central warehouse in Cange, which acts as a hub, until those goods are needed at individual clinics. As annual orders increase in size to support PIH's expanding operations, the limited size of the central warehouse has become a constraint, making a change in current inventory policies necessary. In order to formulate revised inventory policies for PIH's Haiti operations, we developed a spreadsheet model that uses historical consumption data of drugs and medical supplies to forecast demand over the next three years. This demand data is then be used as input to run and compare the existing annual order policy with ordering policies with more frequent reviews. These inventory policies are then evaluated against the central warehouse size constraints to recommend an inventory policy better suited to meet PIH's needs. We find that more frequent orders drastically reduces warehouse space requirements while maintaining high service levels. It is hoped that PIH can continue to use this model to determine future inventory policy needs.

Thesis Supervisor: Jarrod Goentzel

Title: Executive Director, Masters of Engineering in Logistics Program

Acknowledgements

The authors would like to acknowledge the following people: Jarrod Goentzel for his consistent support, advice and recommendations throughout the year; Kathryn Kempton, Jon Lascher and Jesse Greenspan from Partners in Health for meeting with us numerous times and providing invaluable insights; Jérémie Gallien for his recommendations concerning our analysis; Bill Haas for his helpful advice regarding our writing; and Apichart Jearasatit for his invaluable insights regarding our charts and tables.

Table of Contents

| | |
|---|----|
| Abstract | 2 |
| Acknowledgements..... | 3 |
| List of Figures | 5 |
| List of Tables | 6 |
| 1 Introduction..... | 7 |
| 2 Literature Review..... | 10 |
| 3 Background- Haiti and PIH Operations..... | 15 |
| 3.1 Haiti..... | 15 |
| 3.2 PIH Sites | 16 |
| 3.3 Shipping and Transportation..... | 17 |
| 3.4 Sources of Goods | 18 |
| 4 Methods..... | 19 |
| 4.1 Demand Forecasting: Background..... | 19 |
| 4.2 Demand Forecasting: Application | 21 |
| 4.3 Inventory Policies | 21 |
| 5 Data Analysis | 27 |
| 5.1 Data Sources and Data Accuracy..... | 27 |
| 5.2 Using the Spreadsheet Model | 30 |
| 5.3 Data Analysis Concerns: Missing Product Volumes | 49 |
| 5.4 Storage Capabilities of the Central Warehouse | 49 |
| 5.5 The St. Marc Warehouse..... | 56 |
| 6 Results..... | 58 |
| 7 Additional Factors..... | 65 |
| 7.1 Tracking of Goods | 65 |
| 7.2 January 2010 Earthquake..... | 65 |
| 7.3 Compounding Issues..... | 66 |
| 8 Recommendations and Conclusion..... | 67 |
| 8.1 Central Warehouse..... | 67 |
| 8.2 IDA Order | 67 |
| 8.3 Inventory Policies | 68 |
| References..... | 69 |
| Appendix..... | 70 |

List of Figures

| | |
|---|----|
| Figure 1: PIH Haiti Existing and Proposed Sites..... | 7 |
| Figure 2: The Ten Departments of Haiti..... | 15 |
| Figure 3: Port Au Prince | 17 |
| Figure 4: Historical Demand by Product | 28 |
| Figure 5: Snapshot of Spreadsheet Model and Tabs..... | 31 |
| Figure 6: Annual Demand vs PIH’S Annual Order | 33 |
| Figure 7: Monthly Data (Original Data) | 34 |
| Figure 8: Clean Monthly Data (Replaces Values of Zero with One) | 34 |
| Figure 9: Forecast Model | 36 |
| Figure 10: Original Forecast Output..... | 37 |
| Figure 11: Clean Forecast Output..... | 38 |
| Figure 12: Parameters Tab (Inputs Highlighted In Yellow) | 39 |
| Figure 13: Physical Stock – Monthly (Stockouts Highlighted in Yellow) | 42 |
| Figure 14: Orders Tab | 44 |
| Figure 15: Order Arrival tab | 44 |
| Figure 16: Product Volume under a Monthly Order System | 47 |
| Figure 17: Product Volume under an Annual Order System | 47 |
| Figure 18: Central Warehouse (Cange) | 50 |
| Figure 19: Central Warehouse Floor Plan | 51 |
| Figure 20: Shelving in the Central Warehouse..... | 52 |
| Figure 21: Shelving Footprint, including interior aisles (all dimensions in meters) | 53 |
| Figure 22: Floor Storage in the Central Warehouse | 55 |
| Figure 23: Exterior of the St. Marc Warehouse (during construction) | 56 |
| Figure 24: Interior of the St. Marc warehouse (during construction) | 57 |
| Figure 25: St. Marc Warehouse Layout..... | 57 |
| Figure 26: Warehouse Inventory Volumes by Inventory Policy | 59 |
| Figure 27: Quantity of Amoxicillin by Inventory Policy..... | 60 |
| Figure 28: Warehouse Inventory Volume with Confidence Bands | 60 |
| Figure 29: Emergency Procurement Costs by Inventory Policy..... | 62 |
| Figure 30: Trade-Off Between Inventory Volume and Emergency Procurement Costs | 62 |
| Figure 31: Emergency Procurement Costs with Confidence Bands | 63 |
| Figure 32: Monthly Containers by Inventory Policy Under 1 Simulation..... | 64 |
| Figure 33: Monthly Incoming Containers with Confidence Bands | 64 |

List of Tables

| | |
|---|----|
| Table 1: PIH Haiti Sites, By Region | 16 |
| Table 2: Comparison of Reorder Point References | 24 |
| Table 3: Data for Efavirenz 200mg and Didanosine 200mg switched in March 2008..... | 29 |
| Table 4: Size 7 gloves used as a substitute for size 7.5 gloves in November and December..... | 29 |
| Table 5: Overview and Description of Tabs in the Model..... | 31 |
| Table 6: Chi-Square Tests to Assess Normalcy of AZT and Plastic Pipette Demand | 41 |
| Table 7: Average Inventory Volume by Policy from 250 Simulations | 59 |
| Table 8: Average Emergency Procurement Costs from 250 Simulations | 61 |
| Table 9: Annual Containers by Inventory Policy | 63 |

1 Introduction

Partners in Health (PIH) is a global non-profit health care provider. PIH’s work began in the impoverished Central Plateau of Haiti with its Zanmi Lasante (“Partners in Health” in Haitian Kreyol) project. What started as a small medical clinic in Cange in 1985 is now a large healthcare complex. The size of PIH’s network has since increased to nine additional sites throughout Haiti, with Port Au Prince functioning as a cross dock for PIH goods coming into the country (Figure 1). Care is provided free of charge and all patients are accepted. At least two additional sites, one in Mirebalais and one in Verrettes are planned for the near future.




Figure 1: PIH Haiti Existing and Proposed Sites
Source: PIH Haiti ZL Site Map, Google Maps

In the past five years, the number of PIH's clinics in Haiti has nearly doubled, and the number of annual patient encounters has nearly tripled to 2.6 million. PIH's supply chain and inventory strategies, however, have not been altered to accommodate this significant growth. As a result, the supply chain has become strained. Under its current inventory policy, the majority of PIH's products are obtained through an annually placed order. The shipment from this order is received sporadically over the next several months, with the final shipment sometimes not arriving for eight months. Because the products are shipped from the main supplier, International Dispensary Association Foundation (IDA), as they become available, sometimes several containers of product will arrive at once. In one instance, seven containers arrived simultaneously.

All products are stored at a central warehouse located in Cange prior to their distribution to other sites. There have been several incidents recently in which the volume of products coming into the central warehouse has exceeded the storage space there. When the volume of goods arriving at the central warehouse exceeds the storage capacity, the goods must be placed at any sites with available space, making it difficult to accurately track and distribute these goods to the sites where they are needed.

Research conducted in 2009 by a Harvard Business School student provided an analysis of PIH's supply chain through review of stockout rates, consumption data, turnover data and volume calculations. The research concluded that the central warehouse was not sufficiently sized to handle the volume of goods managed by PIH. While the study suggested several options for larger or additional central warehouses, it did not provide a modified inventory policy.

The objective of our thesis is to improve the existing supply chain by developing new inventory policies to support the projected growth of PIH while reducing warehouse volume

requirements and emergency procurement costs. Additionally, in January 2010, a 7.0 Mw earthquake just outside of Port Au Prince, Haiti's capital and largest city, devastated the region. While PIH's sites were not damaged in the earthquake, these sites will be subject to much change in the future. As a result of the earthquake, there is expected to be significant internal migration to the Central Plateau and beyond. Therefore, PIH will need to adjust our demand forecast numbers accordingly once it has a good estimate of the population increase in its catchments areas.

In the seven sections below, we will discuss our approach to improving PIH's supply chain. In section 2, Literature Review, we survey publications that address for-profit and non-profit healthcare operations, especially those covering inventory and supply chain challenges. In section 3, Background-Haiti and PIH Operations, we provide background on Haiti and PIH's role in providing health services in the country. Section 4, Methods, explains the forecasting and inventory theories used for our data analysis. In section 5, Data Analysis, the data cleaning is discussed, and a user guide for the spreadsheet model we developed for forecasting and inventory analysis is provided. This section also provides an overview of available warehouse space. In section 6, Results, the findings of our inventory policy review are summarized. In section 7, Additional Factors, further issues that may affect the inventory policy are discussed. Finally, in section 8, Recommendations, some additional ideas for ways PIH can improve its existing supply chain are provided.

2 Literature Review

Our review of the literature included peer-reviewed publications and field guides developed by public health practitioners. These documents survey current academic research and summarize practices that do or do not work in developing countries. Although there is no “one size fits all” answer for health care supply chains in developing countries, our review provides a context for our analytical techniques.

The application of management science (MS) and operations research (OR) to health care and pharmaceutical practices is becoming widespread. The literature provides the theory behind MS and OR techniques and details successful applications of theory-based practices in health care environments. Carter, Golden and Wasil (2009) surveyed eight successful MS and OR applications in various sectors of the health care industry. Only one was specific to pharmaceuticals, however.

HIV treatment in developing countries is a major objective of some NGOs. PIH has performed much HIV work in Haiti already. One of its early successful interventions in Haiti was HIV treatment in the Central Plateau. Koenig, Leandre and Farmer (2004) discuss the successful scale-up of this HIV treatment program. While this paper is a useful reference, much of the scale-up’s success was due to the hiring of *accompagnateurs*. *Accompagnateurs* are hired to work within their home community, and ensure those receiving medical care in their community are taking their medications per specification and attending scheduled clinic visits. The article did not clearly address the effect the scale-up had on the pharmaceutical supply chain.

World Health Organization (2004) provides a framework for procurement, storage and inventory management of drugs in their “Management of Drugs at Health Centre Level” training manual. Regarding procurement, the concepts of lead time (L), monthly consumption, reorder

points (s) and order-up-to levels (S) are described. Regarding storage, the attributes of the storeroom environment, arrangement of drugs on the shelf, use of a first in first out (FIFO) system is discussed. A FIFO system ensures the drugs that were received first should be used first; as long as more recently received drugs do not have shorter expiration dates. Regarding stock management, how to track inventory by the use of manual stock cards is discussed. PIH's current stock monitoring system (a computerized database with internet linkages), is far more advanced. Therefore, the models explained in the WHO manual are not likely to be pursued.

The role of supply chains in the proper functioning of healthcare system are focused on in papers by Hicks, Purcell, Raja and Heinen (2009) and Hicks, Raja and Heinen (2009). Levine, Pickett, Sekhri and Yadav (2008) also address supply chains in healthcare systems, but narrow their focus to the role of forecasting.

Hicks, Purcell, Raja and Heinen (2009) discuss a scenario in which although significant financing for drugs and supplies and supply chain operations was available, overstocks and stockouts were common. The World Bank and Llamasoft were called upon to analyze the issues in the supply chain. It was fortunate that several years of transaction data was available for analysis of the 3285 products offered. The system was comprised of a hybrid single echelon and a two tiered echelon system. This system was evaluated for efficiency using the supply chain modeling tool Llamasoft. A potential decentralized system and a potential centralized system were also evaluated. The analysis also studied the 20 most demanded products, the fill rates for those items, and their largest customers by volume. Overall, fill rate was about 75%. Llamasoft helped determine that the biggest problems in the system were long lead times and high variability in these lead times from the supplier. Further investigation revealed that the high variability in lead times, if improved, would be the greatest source of savings and improvement

in supply chain quality. Llamasoft also helped to determine that a centralized system in which all goods were shipped from the central storage to the facility, rather than some sites being served by regional storage facilities, would lower overall costs by about 5%. Other portions of the study identified poor ordering habits at the hospital level. Rather than using monthly orders to obtain the majority of their supplies, daily rush orders were the norm. Habits like this are to some extent fed by the existing supply chain problem, but also the reason these problems in the supply chain continue. This paper's investigation of over/understock issues, direct vs. regional distribution, and poor ordering habits at the clinic level parallel several investigations we will be performing in our own thesis. Our investigation focuses on a smaller product volume, but involves forecasting future demand and warehouse efficiency.

Hicks, Raja and Heinen (2009) investigated the poor fill rate (21%) within KEMSA (Kenta Medical Supplies Agency) system. In the system, 1173 products were sourced from three central warehouses in Nairobi and eight smaller regional depots (though these were mostly used to hold slower moving items). KEMSA used a push system, in which products were shipped six times a year to hospitals and four times a year to health centers. In KEMSA's view, its current warehouse system was at capacity. The focus of the analysis was to determine whether the system should be decentralized, and whether the push system was the most effective for the system's needs. The decentralization study looked at six scenarios, including the existing scenario (one centralized DC), converting all existing regional depots to DCs, and conducting a "Greenfield" analysis to determine the optimum location of a single warehouse. Analysis revealed that while adding regional warehouses would reduce transportation costs significantly, the savings would be partially offset by higher inventory costs. It was determined that the addition of one regional DC would be a good balance. An analysis was then run eight times at

potential locations to determine the ideal location for this DC. While the other goal of the analysis had been to compare use of a pull system vice a push system, it was determined that the shortage issue was so severe that it should be investigated instead. The analysis confirmed that warehouse space was an issue, as increasing the fulfillment rate from 21% to 100% would require warehouse space to increase to two to three times. As for improving service rate, demand variability was a major culprit, and a significant increase in inventory would be needed to overcome this variability and achieve a 100% service rate. Overall, the study determined that inadequate financing was the root of the problem, and that additional funds were essential to make the supply chain more efficient. The fact that forecasted demand was not accounted for makes the 21% fulfillment rate even more alarming, if not action is taken. This paper reflects many of the concepts we analyze in our thesis, especially its investigation of adequate warehouse space.

Levine, Pickett, Sekhri and Yadav (2008) discuss the importance of reliable demand forecasts for global health programs. Viewing a reliable forecast as critical in the success of a supply chain, the paper elaborates on the effect a poor forecast can have on the entire supply chain. One example given was a pharmaceutical company overproducing a drug based on an inaccurate forecast from a global health program.

While this paper was relevant to our research as it addresses the importance of forecasting, it focuses more on the effects of forecasting further upstream the supply chain than our thesis does. Many examples are cited where the supplier is greatly affected. In our thesis forecasting is important further downstream, to PIH itself. An accurate forecast will allow PIH to better determine demand, and therefore select the most appropriate inventory policy based on that demand.

Morreale and Prichard (1995) provide rules of thumb for logistics topics ranging from transportation to inventory to warehousing. The inventory subjects addressed included inventory levels, service levels, and carrying costs. The guidance provided on warehousing was of particular interest to us. Information included such topics as storage capacity, rack layout, aisle arrangement, available space and cube utilization. The concepts behind available space and cube utilization will be important in our evaluation of the central warehouse.

While the running, improvement, and scale-up of healthcare systems are common subjects in peer-reviewed publications and field guides, most of them do not focus on supply chain improvement. Even fewer address the importance of forecasting within the context of supply chain improvement. In our thesis, we use forecasting to develop more appropriate inventory policies for PIH while remaining cognizant of the constraints of warehouse size.

3 Background- Haiti and PIH Operations

PIH has been active in Haiti for over twenty years. This section provides a basic background on Haiti and on PIH's efforts there. Current and proposed PIH sites are discussed, as are PIH's existing system for distributing goods throughout that system. Finally, sources of PIH's goods are discussed.

3.1 Haiti

Haiti occupies the western portion of the Caribbean island of Hispaniola. Haiti has long suffered from political violence and poverty, and is considered the poorest country in the Americas. The current population is approximately 9 million. The largest city, and capital, is Port Au Prince. Haiti is divided into ten departments, including the Artibonite and Centre departments that PIH serves (Figure 2). Haitian Creole and French are the official languages. PIH operates eight sites in the Central Plateau and two sites in the Artibonite region of Haiti.



Figure 2: The Ten Departments of Haiti

<http://upload.wikimedia.org/wikipedia/commons/d/de/Haiti_departments_named.png>

3.2 PIH Sites

PIH operates eight sites throughout the Central Plateau of Haiti: Belladere, Boucan Carre, Cange, Cerca La Source, Hinche, La Colline, Lascahobas and Thomonde. PIH also operates two sites in the Artibonite region: Petite Riviere and Saint Marc. Facilities vary at each site, as described below in Table 1.

Table 1: PIH Haiti Sites, By Region

Central Plateau Sites

| Site Name | Medical Facility Type | Storage Facility Type | Comments |
|-----------------|------------------------------|-------------------------|--|
| Belladere | clinic | storage space | |
| Boucan Carre | clinic (small) | storage space | difficult to reach due to poor road conditions |
| Cange | Sociomedical Complex | warehouse | |
| Cerca La Source | hospital | warehouse | remote site |
| Hinche | hospital | warehouse (large) | |
| La Colline | hospital (new, full service) | storage space | also acts as main storage for Lascahobas |
| Lascahobas | women's health facility | storage space | ten minutes from La Colline |
| Thomonde | clinic (small) | storage space (limited) | |

Artibonite Sites

| Site Name | Medical Facility Type | Storage Facility Type |
|----------------|-----------------------|-------------------------|
| Petite Riviere | clinic (small) | storage space (limited) |
| Saint Marc | hospital (large) | warehouse (large) |

Future sites will likely be established in Mirebalais (Central Plateau) and Verrettes (Artibonite) to address the need for health care services in these areas. In addition, a large warehouse may also be located in Mirebalais.

All PIH products are shipped into Port Au Prince, which is located in the Quest department (Figure 3). Prior to the earthquake, PIH operated one small facility in Port Au Prince. This facility acted as a cross dock for goods received. Goods were not stored at this facility, but instead were moved to the warehouse located in Cange.

PIH currently only ships goods into Port Au Prince because of the excellent relationship they maintain with customs at that port. While the use of additional ports has been discussed, it is uncertain whether the organization would be able to develop good relationships in customs at

new ports. Post-earthquake, PIH is renting a large facility in Port Au Prince. It has yet to be determined if such a facility will become permanent.



Figure 3: Port Au Prince

<http://en.wikipedia.org/wiki/File:Haiti_map.png>

PIH’s main site in Haiti is located in Cange. Named the Sociomedical Complex, it is comprised of a full-service hospital (104 beds), an infectious disease center, an outpatient clinic, a women’s health clinic, a laboratory, a Red Cross blood bank, radiographical services, and a large warehouse. As discussed previously, the warehouse in Cange acts as a “central” warehouse. All goods are stored at the Cange warehouse until one of the ten regional sites requests a need for them. They are then transported to that site.

3.3 Shipping and Transportation

The majority of products are shipped to PIH by container ship. This is a cost effective method of sending goods but also has the longest lead time. Some shipments are also made by air, either as air-freight, or carried in suitcases by PIH staff when traveling to Haiti.

Transportation between the central warehouse in Cange and the regional sites is adequate, but could benefit from some improvement. Currently, goods are transported between the central warehouse and the regional sites on a weekly or bi-weekly basis. PIH does not own the majority of these vehicles but rather rents them. This is due in part to the high maintenance required on vehicles that travel unpaved roads of rural Haiti. PIH staff also report that the trips are often made with less than a full load, even when multiple sites could be serviced on the same trip.

3.4 Sources of Goods

Approximately two-thirds of the products in our analysis are supplied by IDA. IDA is the world's leading non-for-profit supplier of affordable pharmaceutical products. PIH places an annual order with IDA in July each year.

PIH also orders goods through McKesson Surgical, Brigham and RxElite. PIH receives in-kind donations as well. Emergency orders are often sourced locally from Haiti or Dominican Republic. PIH also sources some infant formula locally due to storage constraints in the central warehouse. Tuberculosis and AIDS drugs are also obtained outside the IDA order.

4 Methods

In order to assess and improve upon the existing supply chain, we looked to PIH's historical demand data. We then chose an appropriate demand forecasting method, and developed inventory policies based on forecasted demand.

In order to describe our process, we first review three common demand forecasting methods: simple exponential smoothing, exponential smoothing with trend, and the Holt-Winters Smoothing Procedure. We then discuss selection of an appropriate forecast method for PIH, and application of this method to an appropriate inventory policy.

4.1 Demand Forecasting: Background

The exponential smoothing approach to demand forecasting is the most appropriate for our research. Exponential smoothing models are preferable to regression models since they give greater weight to recent data. Silver, Pike and Peterson (1998) discuss three exponential smoothing methods.

Simple exponential smoothing:

$$\text{Underlying model: } x_t = a_t + e_t \quad (1)$$

$$\text{Where: } \hat{a}_{t,t+1} = \alpha x_t + (1-\alpha) \hat{a}_{t-1,t} \quad (2)$$

This model incorporates historical data into projections. Demand is a function of level (a) plus an error term. Higher values of alpha, which ranges from 0 to 1, give more weight to recent demand data. For these equations the “hat” symbol (^) indicates a predicted value for the given variable. In this model, $\hat{a}_{t-1,t}$ is the projected level of a at time (t), based on the projected level at time (t-1) (Silver, Pyke and Peterson 89).

Exponential smoothing with trend:

$$\text{Underlying model: } x_t = a_t + b_t t + e_t \quad (3)$$

$$\text{Where: } \hat{a}_{t,t+1} = \alpha x_t + (1-\alpha)(\hat{a}_{t-1} + \hat{b}_{t-1}) \quad (4)$$

$$\hat{b}_t = \beta(\hat{a}_t - \hat{a}_{t-1}) + (1-\beta)\hat{b}_{t-1} \quad (5)$$

This model builds on simple exponential smoothing by incorporating a trend component (b), which represents the linear increase of demand over time. This approach is appropriate for data in which demand changes linearly over time (Silver, Pyke and Peterson 93). Higher values of beta make the slope component of the model more sensitive to recent changes in demand. The model assumes that demand patterns are somewhat smooth. Although this approach is an improvement upon the simple smoothing model, it is still inappropriate for products with seasonal demand fluctuations.

Holt-Winters Smoothing Procedure:

$$\text{Underlying model: } x_t = (a_t + b_t t)F_t + e_t \quad (6)$$

$$\text{Where: } \hat{a}_{t,t+1} = \alpha(x_t/\hat{F}_{t-p}) + (1-\alpha)(\hat{a}_{t-1} + \hat{b}_{t-1}) \quad (7)$$

$$\hat{b}_t = \beta(\hat{a}_t - \hat{a}_{t-1}) + (1-\beta)\hat{b}_{t-1} \quad (8)$$

$$\hat{F}_t = \gamma(x_t/\hat{a}_t) + (1-\gamma)\hat{F}_{t-p} \quad (9)$$

The Holt-Winters Smoothing Procedure builds on exponential smoothing with trend by incorporating a seasonality component (F). This approach is particularly useful for medical products, such as antimalarials, for which demand peaks during certain times of the year. F is a

function of current demand divided by a moving average of demand. \hat{F}_{t-p} is the value of F at the same time in the preceding period. A period is the length of time of a demand cycle. For instance, if demand has an annual cycle, the period is 12 months, or 1 year. Higher values of gamma give greater weight to recent demand in the seasonality equations.

4.2 Demand Forecasting: Application

The Holt-Winters method was chosen for forecasting PIH's product demand, as demand for some of PIH's products follows a seasonal pattern. Three years (January 2007- December 2009) of historical data were used to forecast demand. Although product demand is somewhat constant across years, it is volatile from month-to-month. For this reason, instead of using the equation $F = (\text{current month's demand} / \text{moving average of demand})$, the numerator in our equation is average demand over a four month period. This time period was chosen to decrease the fluctuations in F, while still allowing some variability over a given year. We use a moving average of 12 months in the denominator of this equation to capture the average monthly demand over a year.

PIH's catchment areas experienced significant internal migration in early 2010 as a result of the Port au Prince earthquake. PIH estimates this migration will cause demand for its service to permanently increase, but does not currently have an estimate for the percent increase.

4.3 Inventory Policies

Currently, PIH places annual orders for its drugs and supplies (PIH staff, personal communication, February 19, 2010). Limiting orders to one annual shipment decreases the complexity of the order management process, but can greatly increase inventory costs. More importantly, PIH's limited warehouse capacity makes it difficult to properly store and monitor

large incoming shipments. This lack of storage space will become a more pressing issue as PIH continues to expand its operations and treat more patients. We therefore investigated the benefits of adopting different inventory policies and order frequencies. The focus of our research is the impact on volume requirements and emergency procurement costs from inventory policy changes. The financial implications of holding excess inventory are not a paramount concern to PIH since it is a non-profit organization.

Since PIH lacks a sophisticated inventory monitoring system, which is discussed in section 7, Additional Factors, we use a periodic review policy for drugs and supplies. Furthermore, periodic reviews allow for easier coordination of several items since orders are placed at the same time for all products (Silver, Pyke and Peterson 241). For this study, we place each product into prioritization categories of A and B. A-items are the most important products and thus maintain higher safety stocks to lower the probability of stocking out. For both category A- and B-items, an (R, s, S) policy is used. Under the (R, s, S) policy, inventory is checked after a set period of time (R) and orders are placed when inventory is below the reorder point (s), whereby:

$$s = X_{L+R} + k * \sigma_{L+R} \tag{10}$$

$X_{(L+R)}$ is demand over lead time (L) and the review period (R), k is a safety factor and σ_{L+R} is the deviation of demand over lead time and the review period. $k * \sigma_{(L+R)}$ is the safety stock, and a higher k corresponds to a higher safety stock (Silver, Pyke and Peterson 245). A-items products are assigned higher k values in order to minimize stockouts. The default k values are 2.33 and 1.65 for A- and B-items, respectively.

The order quantity is equal to the difference of ($S - \text{current inventory} - \text{in-transit inventory}$) at time of the order (Silver, Pyke and Peterson 241). Order quantities under periodic review systems are difficult to optimize. Therefore we devise S as a multiple of s with the multiple being greater than or equal to 1.

Since demand is not constant across months, S changes each review period. $X_{(L+R)}$ depends on the expected demand over the upcoming lead time and review period, while $\sigma_{(L+R)}$ is constant, since variance takes into account all periods of historical demand. Additionally, the order quantity is rounded up to the nearest unit size for practical purposes, since a supplier will not accept an order for a fraction of a package. For example, if a unit or box of penicillin consists of 100 individual pills, then an order quantity of 255 will be rounded up to 300 pills.

For our model, we use a monthly review policy ($R = \text{one month}$) for PIH's products. A shorter review period would be too onerous for PIH given the resources required to conduct an inventory check and place orders (PIH staff, personal communication, March 30, 2010). A review period of greater than one month, however, would lead to greater storage requirements. We also analyze longer review periods in case monthly orders are too demanding for PIH staff in Haiti.

The initial inventory level set to is $X_{(L+R)} + k*\sigma_{(L+R)}$, or the reorder point. This level was chosen so that each product would be ordered in month two while maintaining sufficient stock for a significant time. The inventory is checked for each product on monthly basis since $R = 1$. If the current inventory position is below the reorder point, a new order is placed. The inventory position is equal to the physical inventory in the warehouse plus the in-transit inventory. In-transit inventory consists of products that have been ordered, but have yet to arrive in the warehouse.

The importance of taking in-transit inventory into account is best explained through a simple example. Assume $L =$ three months, and that for a certain product $s = 1000$, $S = s$, monthly demand is 200 and the initial inventory is 1200. If orders are based solely on physical inventory levels, organizations will make excess purchases until the original order is actually received in the warehouse. The table below illustrates how not incorporating in-transit inventories for order placements causes large, unnecessary spikes inventory levels.

Table 2: Comparison of Reorder Point References

| Ordering based on Physical Inventory | | | | | | Ordering based on Inventory Position | | | | | |
|--------------------------------------|--------------------|----------------|------------|---------------|--------|--------------------------------------|--------------------|----------------|------------|---------------|--------|
| Physical Inventory | Inventory Position | Order Quantity | In-transit | Order Arrival | Demand | Physical Inventory | Inventory Position | Order Quantity | In-transit | Order Arrival | Demand |
| 1200 | 0 | 0 | 0 | 0 | 200 | 1200 | 0 | 0 | 0 | 0 | 200 |
| 1000 | 1000 | 0 | 0 | 0 | 200 | 1000 | 1000 | 0 | 0 | 0 | 200 |
| 800 | 800 | 200 | 200 | 0 | 200 | 800 | 800 | 200 | 200 | 0 | 200 |
| 600 | 800 | 400 | 600 | 0 | 200 | 600 | 800 | 200 | 400 | 0 | 200 |
| 400 | 1000 | 600 | 1200 | 200 | 200 | 400 | 800 | 200 | 600 | 200 | 200 |
| 400 | 1400 | 600 | 1600 | 400 | 200 | 400 | 800 | 200 | 600 | 200 | 200 |
| 600 | 1800 | 400 | 1600 | 600 | 200 | 400 | 800 | 200 | 600 | 200 | 200 |
| 1000 | 2000 | 0 | 1000 | 600 | 200 | 400 | 800 | 200 | 600 | 200 | 200 |
| 1400 | 1800 | 0 | 400 | 400 | 200 | 400 | 800 | 200 | 600 | 200 | 200 |
| 1600 | 1600 | 0 | 0 | 0 | 200 | 400 | 800 | 200 | 600 | 200 | 200 |
| 1400 | 1400 | 0 | 0 | 0 | 200 | 400 | 800 | 200 | 600 | 200 | 200 |
| 1200 | 1200 | 0 | 0 | 0 | 200 | 400 | 800 | 200 | 600 | 200 | 200 |

As mentioned previously, forecasted demand is used to determine inventory policies for each product. Forecasted demand is also used to derive simulated demand, where:

$$\text{Simulated demand} = \text{forecasted demand} + Z * \text{standard deviation of demand} \quad (11)$$

Z is the z-score corresponding to a randomly chosen probability of 0 to 1. In our simulations, demand is equal to simulated demand. Simulated demand is utilized to test the robustness of inventory policies regarding stockouts and warehouse volume requirements, the primary

objectives of our research. A stockout occurs whenever PIH's inventory is not sufficient to meet demand for a given product.

Simulations are run under numerous lead time and review period scenarios. The current lead time for PIH's orders is four months, which is the default in our model. We also vary R from one month, three months and six months. Finally we compare these results of these review periods to those from annual orders. Below are the seven scenarios under which we run simulations.

Scenario 1: Monthly orders, $S = s$, $L = 4$ months

Scenario 2: Quarterly orders, $S = s$, $L = 4$ months

Scenario 3: Semi-annual orders, $S = s$, $L = 4$ months

Scenario 4: Monthly orders, $S = s$, $L = 2$ months

Scenario 5: Quarterly orders, $S = s$, $L = 2$ months

Scenario 6: Semi-annual orders, $S = s$, $L = 2$ months

Scenario 7: Annual orders, $Q = D + k\sigma_{\text{year}}$

For annual orders we assume that all products arrive in January and that order quantity is equal to expected annual demand + $k \cdot \text{monthly sigma} \cdot \sqrt{12}$. For each scenario, we capture inventory volume, emergency procurement costs and the number of shipping containers arriving in Port au Prince over 250 simulations.

Product volume is the individual cubic meters of a product multiplied by the number of individual units for that product. The volumes of all products are summed to tabulate the monthly required storage space for the warehouse. The storage space at the central warehouse is limited, and therefore the maximum volume associated with an inventory policy would have to take this constraint into account.

The financial analysis of our research focuses on stockout costs, since they are tangible expenses born by PIH. In the private sector, a stockout often results in a lost sale. In the public health environment, though, there are no “lost” sales. First, there is the component of human suffering or possible death associated with a patient not receiving a necessary drug. Furthermore, PIH must locally source depleted products from Haiti or have them flown in. Both actions place significant financial burdens on PIH. The cost of stockout is B_2 *product value, where B_2 is the markup or penalty from buying locally or flying a product from Boston compared to normal cost of receiving a product via ship. For this analysis we assume a stockout penalty of 50%, which is the average markup for locally procured drugs and supplies in Haiti.

Theoretically, stockouts will decrease with shorter lead times and more frequent orders because PIH can respond more rapidly to low inventory levels. It will also have more numerous opportunities, rather than just one annually, to place orders through its primary suppliers. Our research tests whether this correlation between stockouts and lead times and order frequency holds.

It is important to analyze both lead times and order frequency since they may be negatively correlated. Currently PIH’s suppliers only send shipments when the entire quantity is available for a given product. Therefore suppliers may be able to respond to order requests more quickly if the order quantities are smaller.

5 Data Analysis

This section discusses sources of data, data cleaning, and the application of that data in a spreadsheet that uses forecasting and inventory policies to allow the user to compare various inventory options. This section also discusses the storage capabilities of the central warehouse, as well as a new PIH warehouse in St. Marc.

5.1 Data Sources and Data Accuracy

The main source of data available for our thesis was PIH's online Electronic Medical Records (EMR) system. It is a restricted access system that we were granted use of for the length of our thesis research. The EMR system provides monthly consumption data of all products at each PIH site from December 2001 through the present. For our thesis, we used data from January 2007 to December 2009. While the EMR system had the capability to export to Excel, the exported data was not "clean".

Before analysis could begin, significant data organization and cleaning was undertaken. Historical demand was gathered from the organization's EMR website, while product details and procurement expenses were collected from previous invoices. Demand is measured as the amount requested from the Cange warehouse by the individual clinics.

Data organization was conducted in Microsoft Excel and STATA, a statistical software program. Since PIH has used over 600 products, our analysis only includes items which had demand of at least 250 units in 2009 in order to reduce complexity. We created programs in STATA to automatically eliminate products with insufficient demand and to generate historical demand statistics.

To assess data accuracy we graphed the monthly demand of each product over the past two years. We grouped the charts peak monthly demand so that comparable scales were used across products. The chart analysis revealed which products contained data outliers, each of which we investigated. The charts also revealed that demand is not constant throughout the year, which supports our assumption that demand is seasonal (Figure 4). We therefore chose a demand forecasting model that incorporates seasonality.




Figure 4: Historical Demand by Product

In some instances, it was obvious that the data was mistakenly placed in an adjacent cell. In these cases, we moved the data to the appropriate cell (Table 3). Other times, outliers were due to changes in availability of similar products with different strengths or sizes for a short

period. For example, a surge in consumption of 10mg amoxicillin corresponds with a large drop in 5mg amoxicillin usage. Table 4 shows an example in which similar sized gloves were substituted.

Table 3: Data for Efavirenz 200mg and Didanosine 200mg switched in March 2008

| Type | Product | Aug-07 | Nov-07 | Dec-07 | Jan-08 | Feb-08 | Mar-08 | Apr-08 | May-08 |
|---------|------------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|
| EyeCare | TetracyclineHydrochloride1%5gOther | 360 | 800 | 374 | 272 | 211 | 241 | 345 | 248 |
| EyeCare | Timololeyedrops0.25%10mlOther | 181 | 4 | 4 | 1 | 7 | 65 | 6 | 16 |
| EyeCare | Tropicamideeyedrops0.5%10mlOther | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIV | AZT+3TC300/1501tabTablet | 54523 | 46681 | 50623 | 62597 | 64480 | 72266 | 67342 | 62832 |
| HIV | Abacavir300mgTablet | 12 | 0 | 0 | 0 | 22 | 60 | 90 | 80 |
| HIV | D4T+3TC+NVP(Triomune-40390mgTablet | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIV | Didanosine50mgTablet | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIV | Didanosine200mgTablet | 0 | 0 | 120 | 0 | 60 | 2110 | 60 | 0 |
| HIV | Efavirenz200mgTablet | 2040 | 1290 | 1778 | 1590 | 2161 | 60 | 2251 | 3062 |
| HIV | Efavirenz600mgTablet | 21571 | 20205 | 13455 | 21736 | 22324 | 24086 | 21897 | 22451 |
| HIV | Indinavir400mgTablet | 4320 | 5940 | 2482 | 5760 | 4680 | 3438 | 4210 | 4500 |
| HIV | Lamivudine150mgTablet | 50831 | 61454 | 48748 | 60083 | 61275 | 67292 | 57431 | 63241 |

Table 4: Size 7 gloves used as a substitute for size 7.5 gloves in November and December

| Type | Product | May-09 | Jun-09 | Jul-09 | Aug-09 | Sep-09 | Oct-09 | Nov-09 | Dec-09 |
|------|--------------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|
| SOP | SurgicalGloves-sterile6(size)Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SOP | SurgicalGloves-sterile6.5(size)Other | 2 | 0 | 0 | 0 | 0 | 57 | 144 | 0 |
| SOP | SurgicalGloves-sterile7(size)Other | 446 | 450 | 126 | 175 | 449 | 677 | 2020 | 1489 |
| SOP | SurgicalGloves-sterile7.5(size)Other | 2838 | 3568 | 3228 | 3994 | 2503 | 1513 | 285 | 56 |
| SOP | SurgicalGloves-sterile8(size)Other | 1741 | 1367 | 1032 | 1188 | 1541 | 3314 | 2040 | 694 |
| SOP | SurgicalGloves-sterile8.5(size)Other | 0 | 0 | 0 | 0 | 0 | 11 | 139 | 0 |

Two other measures were taken to ensure data accuracy. First, we compared PIH's weekly consumption data against the monthly consumption data as weekly consumption and monthly consumption are contained in separate databases in the EMR system. When the weekly consumption numbers were aggregated, they equaled the data contained in the monthly consumption database, revealing consistency between the databases. Furthermore, we checked consumption figures from each of the clinics denoted in the EMR system against PIH's aggregate consumption database. We manually aggregated consumption from the individual clinics and found that these data match the data from PIH's aggregate database.

To conduct our data analysis, we linked the product detail database that we created, which includes weight, volume and price, to the historical demand database in order to have an integrated system. Product names across different PIH databases were not similar. For this reason, we created a unique name that is used across all sections of the model. We also created a document that shows a product's unique name, along with the original name used in each database. Having unique names is important so that PIH can efficiently import new demand data to update inventory policies.

5.2 Using the Spreadsheet Model

Our forecasting and inventory policy models were created in Microsoft Excel. The models include macros so that projected demand, inventory policies and simulation outputs are automatically generated. In order to tabulate new projections and policies for each product, the user of the model only needs to update historical data. The user can also specify certain parameters such as lead time (L), number of months between orders (R), order-up-to levels (S), and k. The user can also alter parameters, alpha, beta and gamma, in the demand forecasting model to make the model more or less sensitive to recent demand or seasonal effects. Below is a detailed overview of each of the 29 tabs in the spreadsheet model. Each tab falls under one of five categories: Product Data, Forecasting, Inventory Policies, Simulation Results and Warehouse.

In the following pages, product tabs are described in the order they appear from left to right in the spreadsheet. The last four tabs address the Cange warehouse area and available volume for storage of goods. Only the upper level of the Cange warehouse is considered for storage space. Furthermore, the appendix includes snapshots of tabs that do not have snapshots in this section.

Table 5: Overview and Description of Tabs in the Model

| Category | Tab | Description |
|--------------------|---------------------------------|---|
| Product Data | Product Details | Weight, volume, price of products |
| Product Data | Monthly Data | Historical product demand |
| Product Data | Clean Monthly Data | Cleaned version of historical demand |
| Forecasting | ForecastModel | Generates forecasted demand for a given product |
| Forecasting | ForecastOutput | Forecasted demand over 3 years for each product |
| Forecasting | CleanForecastOutput | Cleaned version of forecasted demand |
| Inventory Policies | Parameters | User sets key parameters such as L, R, k, and B2 |
| Inventory Policies | Reorder Point | Inventory level at which a new order is placed |
| Inventory Policies | Order up to Level | Quantity ordered = S - Inventory Position |
| Inventory Policies | Simulated Demand | Demand simulations for each product |
| Inventory Position | Physical Stock - Monthly Orders | Inventory of each product at the warehouse |
| Inventory Position | Emergency - Monthly Orders | Monthly emergency purchases for each product |
| Inventory Position | Physical Stock - Annual Orders | Inventory of each product at the warehouse with annual orders |
| Inventory Position | Emergency - Annual Orders | Monthly emergency purchases for each product with annual orders |
| Inventory Position | Orders | Monthly orders for each product |
| Inventory Position | Order Arrival | Monthly arrivals of ordered products at the warehouse |
| Inventory Position | Container Arrival | Number of containers that arrive at Port au Prince each month |
| Inventory Position | In Transit Stock | Monthly inventory of in-transit products |
| Inventory Position | Physical + In Transit Stock | Total inventory position |
| Inventory Position | Volume Reqs - Monthly Orders | Volume of inventory in warehouse each month |
| Inventory Position | Volume Reqs - Annual Orders | Volume of inventory in warehouse each month under an annual order policy |
| Simulation Results | Emergency Procurement Sims | Simulation results from each inventory policy for emergency procurement costs |
| Simulation Results | Volume Sims | Simulation results from each inventory policy for volume of warehouse inventory |
| Simulation Results | Container Arrival Sims | Simulation results from each inventory policy for container arrivals |
| Simulation Results | Charts | Charts of simulation results |
| Warehouse | Cange Warehouse Layout | Warehouse wall lengths |
| Warehouse | Cange Shelf Storage | Determines available volume of shelves |
| Warehouse | Cange Available Floor Space | Determines available floor space |
| Warehouse | % Goods Cange | Percentage of goods that remain in the Cange medical complex |

| 1 Description | #Units | UnitQuan | Total | | Single | | Unit | | Total | | Volume - | | Total | | Unit Price/Qu | Price | Unit | Price/Qu | Total Cost | Demand09 |
|---|--------|----------|-----------|------------|------------|----------|------------|--------|-----------|-----------|------------|-------|----------|--|---------------|-------|------|----------|------------|-----------|
| | | | Order | Volume m3 | Volume m3 | Order M3 | Volume | Annual | Weight KG | Weight KG | (In kg) | Price | Quantity | | | | | | | |
| 2 Acetazolamide250mgTablet | 6 | 1000 | 6,000 | 0.00001167 | 0.00166667 | 0.01 | 0.00166667 | 4.5 | 20.03 | 0.02003 | 120.18 | | | | | | | | | |
| 3 Acetylsalicylicacid500mgTablet | 650 | 1000 | 650,000 | 0.00000362 | 0.00061538 | 0.40 | 0.00061538 | 117 | 1.95 | 0.00195 | 1,267.50 | | | | | | | | | 4,820 |
| 4 Acyclovir200mgTablet | 300 | 500 | 150,000 | 0.00000100 | 0.0005 | 0.15 | 0.0005 | 150 | 12.49 | 0.02498 | 3,747.00 | | | | | | | | | 45,654 |
| 5 Amnophylline25mg/ml10mlAmpulle | 50 | 100 | 5,000 | 0.00005000 | 0.0005 | 0.28 | 0.0005 | 97.4 | 44.17 | 0.4417 | 2,208.50 | | | | | | | | | 792 |
| 6 Amoxicillin125mgBottle | 1325 | 40 | 53,000 | 0.00042151 | 0.01698038 | 22.34 | 0.01698038 | 9010 | 19.33 | 0.48325 | 25,612.25 | | | | | | | | | |
| 7 Amoxicillin500mgTablet | 3700 | 1000 | 3,700,000 | 0.00000256 | 0.00255946 | 9.47 | 0.00255946 | 3182 | 33.6 | 0.0336 | 124,320.00 | | | | | | | | | 1,918,142 |
| 8 Amoxiciline/Acicla200/28 5228 5mgTablet | 1000 | 50 | 50,000 | 0.00004160 | 0.00078 | 0.78 | 0.00078 | 125 | 8.72 | 0.1744 | 8,720.00 | | | | | | | | | |
| 9 AmphotecinneB50mgAmpulle | 150 | 1 | 150 | 0.00006667 | 6.6667E-05 | 0.01 | 6.6667E-05 | 3 | 11.51 | 11.51 | 1,726.50 | | | | | | | | | |
| 10 Ampicillin9Other | 1500 | 50 | 75,000 | 0.00005673 | 0.00279667 | 4.18 | 0.00279667 | 2115 | 12.35 | 0.247 | 18,525.00 | | | | | | | | | 37,813 |
| 11 Atenolol50mgTablet | 350 | 1000 | 350,000 | 0.00000666 | 0.00065714 | 0.23 | 0.00065714 | 70 | 6.42 | 0.0642 | 2,247.00 | | | | | | | | | 91,629 |
| 12 PenicillinBenzathine2.4MIUAmpulle | 550 | 50 | 27,500 | 0.00005527 | 0.00276364 | 1.52 | 0.00276364 | 676.5 | 43.06 | 0.8612 | 23,683.00 | | | | | | | | | 5,056 |
| 13 Acidbenzoic6%+Acidsalicylic3%40mgOther | 350 | 10 | 3,500 | 0.00021714 | 0.00217143 | 0.76 | 0.00217143 | 218.8 | 4.05 | 0.405 | 1,417.50 | | | | | | | | | 887 |
| 14 BenzylPenicillin5MIUAmpulle | 100 | 50 | 5,000 | 0.00009600 | 0.0043 | 0.43 | 0.0043 | 206 | 43.34 | 0.8668 | 4,334.00 | | | | | | | | | |
| 15 CalciumGluconate10%1ItemAmpulle | 50 | 20 | 1,000 | 0.00005000 | 0.001 | 0.05 | 0.001 | 16.5 | 4.26 | 0.213 | 213.00 | | | | | | | | | |
| 16 Captopril25mgTablet | 2000 | 100 | 200,000 | 0.0000120 | 0.00012 | 0.24 | 0.00012 | 70 | 1.26 | 0.0126 | 2,520.00 | | | | | | | | | 557,240 |
| 17 Carbamazepine200mgTablet | 250 | 1000 | 250,000 | 0.00000120 | 0.00012 | 0.30 | 0.00012 | 72.5 | 13.82 | 0.01382 | 3,455.00 | | | | | | | | | 82,000 |
| 18 Cephalexine500mgTablet | 700 | 100 | 70,000 | 0.0000243 | 0.00024286 | 0.17 | 0.00024286 | 98 | 10.68 | 0.1068 | 7,476.00 | | | | | | | | | 43,009 |
| 19 Ceftriaxone1gAmpulle | 4000 | 10 | 40,000 | 0.00008200 | 0.00082 | 3.28 | 0.00082 | 720 | 7.89 | 0.789 | 31,560.00 | | | | | | | | | 26,740 |
| 20 Chloramphenicol1gOther | 250 | 50 | 12,500 | 0.00004160 | 0.00208 | 0.52 | 0.00208 | 322 | 20.31 | 0.4062 | 5,077.50 | | | | | | | | | |
| 21 Chloroquine50mg/ml60mlBottle | 40 | 195 | 7,800 | 0.00017821 | 0.03475 | 1.39 | 0.03475 | 660 | 110.96 | 0.569026 | 4,438.40 | | | | | | | | | 10,897 |
| 22 Chloroquine150mgTablet | 480 | 1000 | 480,000 | 0.00000152 | 0.00152083 | 0.73 | 0.00152083 | 216 | 11.24 | 0.01124 | 5,395.20 | | | | | | | | | 244,883 |
| 23 Chlorpromazine25mgTablet | 20 | 1000 | 20,000 | 0.00000050 | 0.0005 | 0.01 | 0.0005 | 4.6 | 5.16 | 0.0516 | 103.20 | | | | | | | | | |
| 24 Ciprofloxacin500mgTablet | 10000 | 100 | 1,000,000 | 0.00000444 | 0.000444 | 4.44 | 0.000444 | 1300 | 4.05 | 0.0405 | 40,500.00 | | | | | | | | | 499,267 |
| 25 Clindamycin150mgTablet | 250 | 100 | 25,000 | 0.00000680 | 0.00068 | 0.17 | 0.00068 | 25 | 38.8 | 0.388 | 9,700.00 | | | | | | | | | 6,736 |
| 26 Clotrimazolevaginal500mg | 4000 | 1 | 4,000 | 0.00013750 | 0.0001375 | 0.55 | 0.0001375 | 116 | 0.4 | 0.4 | 1,600.00 | | | | | | | | | |
| 27 CotrimoxazolTHP/SMX(800/160mg)DS1tabTablet | 4500 | 500 | 2,250,000 | 0.00000327 | 0.00163333 | 7.35 | 0.00163333 | 3375 | 12.28 | 0.02456 | 55,260.00 | | | | | | | | | 938,049 |
| 28 CotrimoxazolTHP/SMX(800/160mg)DS1tabTablet | 1500 | 500 | 750,000 | 0.00000997 | 0.00163333 | 2.44 | 0.00163333 | 1195 | 15.78 | 0.03144 | 18,450.00 | | | | | | | | | 938,049 |

Figure 5: Snapshot of Spreadsheet Model and Tabs

Product Details Tab

This tab contains the unique name, volume, weight and price for each product. The data were collected from PIH's order invoices from IDA and PIH's Google Tracker site, and was entered manually. Other sections of the model draw volume and price data from this tab to calculate stockout costs and volume requirements.

The product details tab also includes a column calculating the ratio of 2009 annual demand to actual order quantity placed by PIH. Although the ratio averages 78%, it varies significantly across products (Figure 6). For some products the ratio is 1%, while it is above 700% for others. A notably low ratio signifies that PIH will have insufficient supply and will incur stockouts and be subsequently forced to place emergency orders for drugs and supplies. A ratio well above 100%, on the other hand, reveals that PIH will have excess inventory and less warehouse space for other items. PIH currently determines order quantity qualitatively through talks with staff in Haiti. Our analysis, however, reveals the importance of quantitative demand forecasting. PIH need not blindly follow our demand forecasts, but it can use them as a base estimate which can then be altered based on the projections of staff in Haiti.

We were unable to obtain volume data for 90 of the 307 products studied in our analysis. Therefore, the inventory volume and emergency procurement costs data produced by the model are underestimates.




Figure 6: Annual Demand vs PIH'S Annual Order

Monthly Data Tab

The Monthly Data tab includes historical monthly demand for each product from January 2007 to December 2009. The data were all gathered from PIH's EMR website under the "Monthly Consumption Report" link. The months run horizontally and products are organized vertically by type of product, such as Eye Care, HIV and Injectables. PIH can update this tab with new demand data to adjust demand forecasts. The tab also includes summary statistics such as annual demand and maximum monthly demand. It should be noted that there may be accuracy concerns with the data. PIH's clinics in Haiti often lack internet access, so consumption figures are not always entered in the EMR system on a regular basis.

Clean Monthly Data Tab

The demand forecast model does not run properly for products that have no demand over a four month period. Therefore, we created the Clean Monthly Data tab, which automatically replaces each monthly demand value of zero from the Monthly Data tab with a value of one.

Cumulatively the replacement of zeros with ones increases historical demand by 0.003%. For the ten products most impacted by this adjustment, the range of increased historical demand is 5.7% - 12.5%. If demand for a given month is greater than zero, this tab simply imports the value from the Clean Monthly Data tab. Figures 7 and 8 below show how this tab updates the Monthly Data tab for values of zero. Other sections of the model use this historical demand data to forecast product demand.

| type | product | Jan-07 | Feb-07 | Mar-07 | Apr-07 | May-07 | Jun-07 | Jul-07 | Aug-07 | Sep-07 | Oct-07 |
|---------|------------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| EyeCare | Gentamycineeyedrops0.3%10mlOther | 503 | 271 | 222 | 381 | 253 | 392 | 323 | 143 | 108 | 288 |
| EyeCare | TetracyclineHydrochloride1%5gOther | 208 | 65 | 106 | 193 | 491 | 282 | 127 | 360 | 490 | 640 |
| EyeCare | Timololeyedrops0.25%10mlOther | 131 | 50 | 15 | 59 | 141 | 9 | 109 | 181 | 23 | 102 |
| HIV | Abacavir300mgTablet | 10 | 30 | 34 | 90 | 21 | 20 | 20 | 12 | 20 | 20 |
| HIV | AZT+3TC300/1501tabTablet | 46282 | 41711 | 42208 | 56599 | 55895 | 55423 | 65904 | 54523 | 56504 | 67737 |
| HIV | Didanosine200mgTablet | 0 | 60 | 120 | 120 | 0 | 60 | 120 | 0 | 60 | 0 |
| HIV | Efavirenz200mgTablet | 2004 | 1530 | 2130 | 1828 | 1911 | 1451 | 2010 | 2040 | 1920 | 1560 |
| HIV | Efavirenz600mgTablet | 17245 | 16518 | 16013 | 21398 | 18336 | 19074 | 20949 | 21571 | 18974 | 23819 |
| HIV | Indinavir400mgTablet | 5040 | 4320 | 3060 | 4320 | 3960 | 5220 | 4500 | 4320 | 3966 | 4726 |
| HIV | Lamivudine150mgTablet | 61999 | 56641 | 56742 | 72405 | 53787 | 52616 | 61592 | 50831 | 56632 | 61813 |

Figure 7: Monthly Data (Original Data)

| type | product | Jan-07 | Feb-07 | Mar-07 | Apr-07 | May-07 | Jun-07 | Jul-07 | Aug-07 | Sep-07 | Oct-07 |
|---------|------------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| EyeCare | Gentamycineeyedrops0.3%10mlOther | 503 | 271 | 222 | 381 | 253 | 392 | 323 | 143 | 108 | 288 |
| EyeCare | TetracyclineHydrochloride1%5gOther | 208 | 65 | 106 | 193 | 491 | 282 | 127 | 360 | 490 | 640 |
| EyeCare | Timololeyedrops0.25%10mlOther | 131 | 50 | 15 | 59 | 141 | 9 | 109 | 181 | 23 | 102 |
| HIV | Abacavir300mgTablet | 10 | 30 | 34 | 90 | 21 | 20 | 20 | 12 | 20 | 20 |
| HIV | AZT+3TC300/1501tabTablet | 46282 | 41711 | 42208 | 56599 | 55895 | 55423 | 65904 | 54523 | 56504 | 67737 |
| HIV | Didanosine200mgTablet | 1 | 60 | 120 | 120 | 1 | 60 | 120 | 1 | 60 | 1 |
| HIV | Efavirenz200mgTablet | 2004 | 1530 | 2130 | 1828 | 1911 | 1451 | 2010 | 2040 | 1920 | 1560 |
| HIV | Efavirenz600mgTablet | 17245 | 16518 | 16013 | 21398 | 18336 | 19074 | 20949 | 21571 | 18974 | 23819 |
| HIV | Indinavir400mgTablet | 5040 | 4320 | 3060 | 4320 | 3960 | 5220 | 4500 | 4320 | 3966 | 4726 |
| HIV | Lamivudine150mgTablet | 61999 | 56641 | 56742 | 72405 | 53787 | 52616 | 61592 | 50831 | 56632 | 61813 |

Figure 8: Clean Monthly Data (Replaces Values of Zero with One)

Forecast Model Tab

This tab generates forecasted demand for each product over a two year horizon. The methodology used is the same as described in the “Demand Forecasting” component of the Methods section earlier in this paper. We created a “Forecast” macro that automatically imports monthly data from 2007 – 2009 into this tab, with each product being imported separately. There are columns for the moving average of demand, seasonality factor (F), level demand (a) and the trend of demand over time (b). The model also incorporates more recent data to renormalize F.

Output appears in the “Forecast(t)” column at the right side of the model (Figure 9). This column displays the monthly forecasted demand for a given product. Once demand has been forecasted for a product, the macro imports historical demand from the “Clean Monthly Data” tab for the next product.

The user can also adjust the values for alpha, beta and gamma. Alpha determines how sensitive the level of demand is to recent data, beta determines the sensitivity of demand trends to recent data, and gamma determines the sensitivity of F to recent data. The forecast runs from February 2010 to December 2012 and the duration of the forecast can easily be increased by copying the “Forecast(t)” column (column Q) to cells further down.




Figure 9: Forecast Model

Forecast Output Tab

The “Forecast” macro automatically imports the data from the “Forecast(t)” column in the “Forecast Model” tab into the “Forecast Output” tab. The layout of this tab is similar to that

of the “Monthly Data” tab with months running horizontally and products running vertically organized by type. The tab contains the demand forecasts for each product.

Clean Forecast Output Tab

Forecasted demand is negative for some products for which demand decreases over time. This forecast of negative demand is a problem for two reasons. First, actual demand for a product cannot be less zero. Second, the inventory policy model is thrown off by negative values, specifically when calculating inventory volume. Therefore this tab changes negative values in the “Forecast Output” tab to zero (Figures 10 and 11).

| Type | Product | Feb-10 | Mar-10 | Apr-10 | May-10 | Jun-10 | Jul-10 | Aug-10 |
|---------|--|---------|---------|---------|---------|---------|---------|---------|
| EyeCare | Gentamycineeyedrops0.3%10mlOther | 160 | 174 | 197 | 234 | 247 | 225 | 208 |
| EyeCare | TetracyclineHydrochloride1%5gOther | 244 | 253 | 299 | 346 | 320 | 299 | 320 |
| EyeCare | Timololeyedrops0.25%10mlOther | 40 | 40 | 36 | 38 | 52 | 59 | 59 |
| HIV | Abacavir300mgTablet | 461 | 620 | 762 | 856 | 852 | 646 | 636 |
| HIV | AZT+3TC300/1501tabTablet | 105,361 | 110,128 | 117,311 | 122,931 | 127,936 | 127,622 | 127,743 |
| HIV | Didanosine200mgTablet | 56 | 49 | 45 | 44 | 69 | 80 | 80 |
| HIV | Efavirenz200mgTablet | 5,352 | 4,417 | 2,345 | 1,045 | 2,319 | 3,280 | 3,243 |
| HIV | Efavirenz600mgTablet | 38,685 | 41,470 | 46,364 | 49,921 | 51,692 | 49,588 | 48,777 |
| HIV | Indinavir400mgTablet | 4,229 | 4,270 | 4,180 | 4,242 | 4,509 | 4,531 | 4,414 |
| HIV | Lamivudine150mgTablet | 114,320 | 109,801 | 109,583 | 112,356 | 116,608 | 111,266 | 109,488 |
| HIV | LamivudineSuspension10mg/10ml240mlBottle | 98 | 111 | 120 | 120 | 123 | 97 | 76 |
| HIV | Lopinavir/Ritonavir250mgTablet | 15,978 | 16,373 | 17,022 | 17,039 | 17,535 | 8,754 | 9,636 |
| HIV | Nevirapine200mgTablet | 115,468 | 118,465 | 122,331 | 125,438 | 127,362 | 125,891 | 126,220 |
| HIV | Nevirapinesusp50mg/5ml240mlBottle | 34 | 32 | 35 | 38 | 39 | 37 | 35 |
| HIV | Stavudine30mgCapsule | 105,205 | 111,996 | 126,096 | 147,920 | 178,345 | 196,959 | 211,302 |
| HIV | Stavudine40mgTablet | -1,531 | -3,450 | -6,780 | -13,756 | -13,256 | -15,066 | -12,225 |
| HIV | Tenofovir300mgTablet | 2,596 | 2,634 | 2,755 | 2,848 | 3,093 | 3,016 | 2,923 |
| HIV | Zidovudine300mgCapsule | 12,089 | 7,637 | 6,420 | 7,491 | 4,871 | 3,487 | 4,670 |
| HIV | Zidovudinesuspension200mlBottle | 145 | 168 | 191 | 201 | 217 | 190 | 144 |

Figure 10: Original Forecast Output

| Type | Product | Feb-10 | Mar-10 | Apr-10 | May-10 | Jun-10 | Jul-10 | Aug-10 |
|---------|--|---------|---------|---------|---------|---------|---------|---------|
| EyeCare | Gentamycineeyedrops0.3%10mlOther | 160 | 174 | 197 | 234 | 247 | 225 | 208 |
| EyeCare | TetracyclineHydrochloride1%5gOther | 244 | 253 | 299 | 346 | 320 | 299 | 320 |
| EyeCare | Timololeyedrops0.25%10mlOther | 40 | 40 | 36 | 38 | 52 | 59 | 59 |
| HIV | Abacavir300mgTablet | 461 | 620 | 762 | 856 | 852 | 646 | 636 |
| HIV | AZT+3TC300/1501tabTablet | 105,361 | 110,128 | 117,311 | 122,931 | 127,936 | 127,622 | 127,743 |
| HIV | Didanosine200mgTablet | 56 | 49 | 45 | 44 | 69 | 80 | 80 |
| HIV | Efavirenz200mgTablet | 5,352 | 4,417 | 2,345 | 1,045 | 2,319 | 3,280 | 3,243 |
| HIV | Efavirenz600mgTablet | 38,685 | 41,470 | 46,364 | 49,921 | 51,692 | 49,588 | 48,777 |
| HIV | Indinavir400mgTablet | 4,229 | 4,270 | 4,180 | 4,242 | 4,509 | 4,531 | 4,414 |
| HIV | Lamivudine150mgTablet | 114,320 | 109,801 | 109,583 | 112,356 | 116,608 | 111,266 | 109,488 |
| HIV | LamivudineSuspension10mg/10ml240mlBottle | 98 | 111 | 120 | 120 | 123 | 97 | 76 |
| HIV | Lopinavir/Ritonavir250mgTablet | 15,978 | 16,373 | 17,022 | 17,039 | 17,535 | 8,754 | 9,636 |
| HIV | Nevirapine200mgTablet | 115,468 | 118,465 | 122,331 | 125,438 | 127,362 | 125,891 | 126,220 |
| HIV | Nevirapinesusp50mg/5ml240mlBottle | 34 | 32 | 35 | 38 | 39 | 37 | 35 |
| HIV | Stavudine30mgCapsule | 105,205 | 111,996 | 126,096 | 147,920 | 178,345 | 196,959 | 211,302 |
| HIV | Stavudine40mgTablet | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIV | Tenofovir300mgTablet | 2,596 | 2,634 | 2,755 | 2,848 | 3,093 | 3,016 | 2,923 |
| HIV | Zidovudine300mgCapsule | 12,089 | 7,637 | 6,420 | 7,491 | 4,871 | 3,487 | 4,670 |
| HIV | Zidovudinesuspension200mlBottle | 145 | 168 | 191 | 201 | 217 | 190 | 144 |

Figure 11: Clean Forecast Output

Parameters Tab

The “Parameters” tab contains the user-set parameters for inventory policies. The parameters, which are highlighted in yellow in the model, include stockout penalty percentage (B_2), k for A-items and B-items, lead time in terms of months (L), review period in terms of months (R), and the ratio of S/s (Figure 12). Items were determined as A-items or B-items based on directions from PIH, who referred us to the Daily Report the EMR system compiled for each site. PIH considers the products tracked in this Daily Report to be “essential” items of which they cannot stock out.

If $R = 1$, orders will be placed every month that the inventory position is below the reorder point. If $R = 3$ orders will be only placed quarterly. Although the default for R is 1, PIH can adjust this value if monthly orders are too cumbersome. An increase in k will lead to an increase in safety stock and inventory volume, but a reduction in emergency purchases. PIH can also adjust B_2 from the default value of 50% if emergency procurement markups deviate from this average.

Actual stockout figures, inventory volume and total emergency procurement costs are calculated automatically in the “Parameters” tab. Further down in the sheet are k values, standard deviations of demand, safety stocks, purchase costs, transportation costs and unit sizes for each product. For products for which we lack unit sizes, we assume 100 individual items per unit.

This tab also includes parameters for inventory holding costs (r), order cost (A), shipping costs, and the volume of a shipping container. The inputs can be adjusted if PIH wants to see additional financial implications of inventory policies and the number of containers required per shipment.

| | |
|------------------------------------|---------|
| r | 0.15 |
| A (total) | 200 |
| Number products/order | 100 |
| Shipping Cost/m3 | 133.60 |
| Container Volume (m3) | 55 |
| Stockout Penalty/Markup (B2) | 50% |
| k: A-items | 2.33 |
| k: B-items | 1.65 |
| Stockout % A-items | 0.816% |
| Stockout % B-items | 2.929% |
| Average Volume | 84.0 |
| Lead Time (months) | 4 |
| Review Period (months) | 1 |
| L+R | 5.0 |
| Order-up-to/Reorder Point (S/s) | 1.0 |
| Annual Emergency Procurement Costs | \$4,936 |
| Average Containers/Month | |

| Type | Product | Class | pu(k) | k | sigma | r | Safety stock | | | A | Actual | Sim | |
|---------|------------------------------|-------|-------|------|-------|------|--------------|------------|-----------|----------|----------|----------|----------|
| | | | | | | | (k*sigma) | v(product) | v(transp) | | v(total) | UnitSize | UnitSize |
| EyeCare | Gentamycineeyedrops0.3%10 | B | 1.65 | 1.65 | 140 | 0.15 | 516 | 0.425 | 0.008016 | 0.433016 | 2 | 100 | 100 |
| EyeCare | TetracyclineHydrochloride1%5 | B | 1.65 | 1.65 | 153 | 0.15 | 563 | 0.2568 | 0.005961 | 0.262761 | 2 | 50 | 50 |
| EyeCare | Timololeyedrops0.25%10mlOt | B | 1.65 | 1.65 | 46 | 0.15 | 170 | 1.88 | 0.002672 | 1.882672 | 2 | 1 | 1 |

Figure 12: Parameters Tab (Inputs Highlighted In Yellow)

Reorder Point Tab

This tab automatically calculates every product’s monthly reorder point, or s. As discussed previously $s = X_{(L+R)} + k \cdot \sigma_{(L+R)}$ and changes monthly because forecasted demand changes over time. The formula for reorder points in the model is lengthy since s is dependent upon the values of L and R. Longer lead times and review periods mean that s incorporates more months of forecasted demand and thus requires several “if” statements in Excel. Whenever

product inventory falls below the respective s in a review period, a new order is placed automatically in the “Orders” tab.

Order up to Level Tab

The formula to determine S is simple. It is merely the S/s ratio, defined by the user in the “Parameters” tab, multiplied by the relevant month’s s . Since S is determined by s , there is a different value for each month and each product. Data from this tab is used to calculate the order quantity.

Simulated Demand Tab

If the model used the exact forecasted demand numbers in consumption simulations, there would never be a stockout since s and S are based on forecasted demand plus a safety stock component. Therefore we use simulated demand in our simulations to test the robustness of inventory policies on inventory volume, emergency procurement costs and other benchmarks.

We created a “Simulations” macro that automatically generates random numbers from 0 to 1 at the bottom of the “Simulated Demand” tab. A unique random number assigned to each product and each month. The tab incorporates these random numbers to calculate simulated monthly demand for each product via the excel function $\text{MAX}(\text{NORMINV}(\text{Random number}, \text{Forecasted demand}, \text{Standard deviation of demand}), 0)$. Since the formula for simulated demand can generate negative values, we use the max of zero or the simulated demand for each month. This function assumes that demand follows a normal distribution. The table below shows that demand for the drug AZT and plastic pipettes are distributed normally since the chi-square value

is well below the threshold of 9.49, assuming four degrees of freedom, for rejecting the null hypothesis that demand is distributed normally.

Table 6: Chi-Square Tests to Assess Normalcy of AZT and Plastic Pipette Demand

| <u>Bin</u> | <u>Frequency</u> | <u>Expected Freq</u> | <u>X2</u> | <u>Bin</u> | <u>Frequency</u> | <u>Expected Freq</u> | <u>X2</u> |
|------------|------------------|----------------------|-------------|------------|------------------|----------------------|-------------|
| 40000 | 1 | 2.32 | 0.75 | 2000 | 4 | 3.46 | 0.09 |
| 60000 | 10 | 8.35 | 0.33 | 4000 | 10 | 10.52 | 0.03 |
| 80000 | 14 | 13.56 | 0.01 | 6000 | 15 | 13.72 | 0.12 |
| 100000 | 8 | 9.03 | 0.12 | 8000 | 5 | 6.88 | 0.51 |
| 120000 | 3 | 2.45 | 0.12 | 10000 | 2 | 1.32 | 0.35 |
| | | | 1.33 | | | | 1.10 |

Physical Stock – Monthly Orders Tab

This tab calculates the number of items for each product that are physically in the warehouse for each month. The physical inventory is equal to the previous month’s inventory – simulated demand for the month + orders arriving at the warehouse at the beginning of the month. Since simulated demand differs from forecasted demand, inventory levels occasionally drop below zero, signifying a stockout (Figure 13). Columns AM-AP of the tab shows the minimum inventory level over the two years, the number of stockouts, the CSL and cumulative shortage for each product. These numbers are summarized in the “Parameters” tab.

| Type | Product | 2/28/2010 | 3/31/2010 | 4/30/2010 | 5/31/2010 | 6/30/2010 | 7/31/2010 | 8/31/2010 |
|---------|--|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| EyeCare | Gentamycineeyedrops0.3%10mlOther | 1,543 | 1,413 | 1,120 | 793 | 793 | 2,304 | 2,195 |
| EyeCare | TetracyclineHydrochloride1%5gOther | 1,935 | 1,891 | 1,693 | 1,241 | 981 | 3,356 | 2,983 |
| EyeCare | Timololeyedrops0.25%10mlOther | 408 | 295 | 261 | 197 | 136 | 582 | 546 |
| HIV | Abacavir300mgTablet | 3,455 | 2,542 | 1,682 | 989 | 162 | 4,891 | 4,423 |
| HIV | AZT+3TC300/1501tabTablet | 604,499 | 518,754 | 384,826 | 276,728 | 162,098 | 860,553 | 713,263 |
| HIV | Didanosine200mgTablet | 498 | 409 | 253 | 172 | 105 | 658 | 543 |
| HIV | Efavirenz200mgTablet | 61,838 | 61,838 | 61,838 | 52,557 | 52,557 | 128,298 | 121,991 |
| HIV | Efavirenz600mgTablet | 222,955 | 189,376 | 165,189 | 121,313 | 76,559 | 385,357 | 326,524 |
| HIV | Indinavir400mgTablet | 23,417 | 19,268 | 15,256 | 11,100 | 6,834 | 31,311 | 27,400 |
| HIV | Lamivudine150mgTablet | 563,575 | 465,213 | 365,668 | 243,502 | 96,360 | 779,167 | 675,589 |
| HIV | LamivudineSuspension10mg/10ml240mlBottle | 572 | 460 | 354 | 224 | 130 | 787 | 704 |
| HIV | Lopinavir/Ritonavir250mgTablet | 79,694 | 60,965 | 38,892 | 21,711 | 221 | 92,037 | 78,026 |
| HIV | Nevirapine200mgTablet | 623,584 | 550,992 | 448,770 | 293,782 | 188,401 | 902,509 | 752,190 |
| HIV | Nevirapinesusp50mg/5ml240mlBottle | 192 | 158 | 113 | 81 | 63 | 326 | 299 |
| HIV | Stavudine30mgCapsule | 733,825 | 605,093 | 517,809 | 377,261 | 197,563 | 1,108,094 | 866,690 |
| HIV | Stavudine40mgTablet | 122,219 | 84,127 | 23,854 | -20,207 | -20,207 | 173,993 | 173,993 |
| HIV | Tenofovir300mgTablet | 13,391 | 9,957 | 5,827 | 2,099 | -1,745 | 15,681 | 13,256 |
| HIV | Zidovudine300mgCapsule | 62,112 | 58,080 | 52,413 | 52,413 | 35,710 | 104,810 | 104,810 |
| HIV | Zidovudinesuspension200mlBottle | 1,055 | 836 | 673 | 443 | 165 | 1,344 | 1,268 |

Figure 13: Physical Stock – Monthly (Stockouts Highlighted in Yellow)

Emergency – Monthly Orders Tab

This tab calculates the amount of emergency purchases in the event of a stockout. If there is a negative inventory for any product in the warehouse, an emergency purchase is automatically placed. The magnitude of the emergency purchase is only intended to cover an inventory shortfall for the given month, so that it does not augment any in-transit inventory. The right side of the tab shows the cumulative amount of emergency purchases and the emergency procurement costs for each product. The emergency procurement costs are the penalty or markup over the normal purchase price and are equal to purchase quantity*purchase price*B₂.

Physical Stock – Annual Orders Tab

This tab reveals the physical inventory level of each product under an annual order system and was created to compare the inventory volume and emergency procurement costs associated with monthly and annual orders. A month's inventory position equals the prior month's inventory – simulated demand + emergency purchases. Each January, an annual

shipment of each product arrives at the warehouse. The magnitude of this shipment is equal to forecasted annual demand + annual safety stock – current inventory position.

Emergency – Annual Orders Tab

This tab is similar to the “Emergency – Monthly Orders” tab, but the size of the emergency purchase is different. Here, the order quantity is equal to the shortage + $S * ((\text{months remaining in the year}) / (L+R))$. For example, if a product has a shortfall of 300 in October the emergency purchase will be $300 + S*2 / (L+R)$ since there are two months until the next shipment arrives in January.

Orders Tab

This tab determines when product orders are placed and is thus crucial in minimizing stockouts and excess inventory. If the sum of inventory in the warehouse plus the in-transit inventory is less than the current month’s reorder point, an order is made. The size of the order is equal to $S - \text{inventory position}$. Furthermore, the order size must be a multiple of the unit size for a given product. The model accomplishes this by rounding up the order quantity to the nearest multiple of the unit size. The model is also set up so that orders can only be placed if the number of the current month is a multiple of R.

Order Arrival Tab

The “Order Arrival” tab calculates when a shipment will arrive in PIH’s warehouse. Lead times and order date are used to determine when the order will actually arrive. For example, with a lead time of 4 months an order placed in June will arrive in October. The model is able to

automatically calculate the arrival time through a series of “If” statements in Excel. Figures 14 and 15 below assume L = 4 and illustrate how the “Orders” and “Order Arrival” tabs interact.

| Type | Product | 3/1/2010 | 4/1/2010 | 5/1/2010 | 6/1/2010 | 7/1/2010 | 8/1/2010 |
|---------|--------------------------------------|----------|----------|----------|----------|----------|----------|
| EyeCare | Gentamycineeyedrops0.3%10mlOther | 300 | 200 | 400 | 200 | 100 | 300 |
| EyeCare | TetracyclineHydrochloride1%5gOther | 200 | 250 | 500 | 500 | 500 | 150 |
| EyeCare | Timololeyedrops0.25%10mlOther | 49 | 51 | 125 | 136 | 0 | 72 |
| HIV | Abacavir300mgTablet | 800 | 800 | 400 | 400 | 400 | 200 |
| HIV | AZT+3TC300/1501tabTablet | 146,000 | 108,600 | 102,000 | 118,900 | 136,600 | 85,400 |
| HIV | Didanosine200mgTablet | 100 | 0 | 100 | 0 | 0 | 100 |
| HIV | Efavirenz200mgTablet | 16,900 | 21,400 | 9,600 | 1,800 | 700 | 500 |
| HIV | Efavirenz600mgTablet | 51,000 | 56,000 | 37,300 | 46,400 | 51,200 | 38,200 |
| HIV | Indinavir400mgTablet | 4,300 | 5,500 | 3,800 | 3,600 | 3,000 | 4,600 |
| HIV | Lamivudine150mgTablet | 147,900 | 120,400 | 105,000 | 98,400 | 120,000 | 152,900 |
| HIV | LamivudineSuspension10mg/10ml240mlBo | 200 | 100 | 0 | 200 | 0 | 100 |
| HIV | Lopinavir/Ritonavir250mgTablet | 6,900 | 12,500 | 13,400 | 16,400 | 14,300 | 19,900 |
| HIV | Nevirapine200mgTablet | 139,500 | 108,200 | 117,800 | 110,200 | 102,800 | 136,800 |
| HIV | Nevirapinesusp50mg/5ml240mlBottle | 100 | 0 | 100 | 0 | 0 | 100 |
| HIV | Stavudine30mgCapsule | 213,400 | 172,800 | 100,200 | 37,400 | 106,600 | 84,500 |

Figure 14: Orders Tab

| Type | Product | 3/1/2010 | 4/1/2010 | 5/1/2010 | 6/1/2010 | 7/1/2010 | 8/1/2010 |
|---------|--------------------------------------|----------|----------|----------|----------|----------|----------|
| EyeCare | Gentamycineeyedrops0.3%10mlOther | 0 | 0 | 0 | 0 | 300 | 200 |
| EyeCare | TetracyclineHydrochloride1%5gOther | 0 | 0 | 0 | 0 | 200 | 250 |
| EyeCare | Timololeyedrops0.25%10mlOther | 0 | 0 | 0 | 0 | 49 | 51 |
| HIV | Abacavir300mgTablet | 0 | 0 | 0 | 0 | 800 | 800 |
| HIV | AZT+3TC300/1501tabTablet | 0 | 0 | 0 | 0 | 146,000 | 108,600 |
| HIV | Didanosine200mgTablet | 0 | 0 | 0 | 0 | 100 | 0 |
| HIV | Efavirenz200mgTablet | 0 | 0 | 0 | 0 | 16,900 | 21,400 |
| HIV | Efavirenz600mgTablet | 0 | 0 | 0 | 0 | 51,000 | 56,000 |
| HIV | Indinavir400mgTablet | 0 | 0 | 0 | 0 | 4,300 | 5,500 |
| HIV | Lamivudine150mgTablet | 0 | 0 | 0 | 0 | 147,900 | 120,400 |
| HIV | LamivudineSuspension10mg/10ml240mlBo | 0 | 0 | 0 | 0 | 200 | 100 |
| HIV | Lopinavir/Ritonavir250mgTablet | 0 | 0 | 0 | 0 | 6,900 | 12,500 |
| HIV | Nevirapine200mgTablet | 0 | 0 | 0 | 0 | 139,500 | 108,200 |
| HIV | Nevirapinesusp50mg/5ml240mlBottle | 0 | 0 | 0 | 0 | 100 | 0 |
| HIV | Stavudine30mgCapsule | 0 | 0 | 0 | 0 | 213,400 | 172,800 |

Figure 15: Order Arrival tab

Container Arrival Tab

The “Container Arrival” tab calculates the projected number of containers that will arrive at Port au Prince every month. First, the tab calculates the volume of each product arriving at the

port for a given month. The number of containers is equal to the sum of the arriving order volume divided by 55 m^3 , an approximate usable amount of available space in a shipping container. This tab does not include the volume of products for which we do not have volume data.

In-Transit Stock Tab

The “In-Transit Stock” tab measures the inventory that has been ordered, but not yet arrived in the warehouse. As mentioned previously, it is important to track this amount to prevent numerous orders from being placed for the same inventory shortfall. The in-transit inventory for a month is equal to the previous month’s in-transit inventory + new orders – orders that arrived in the current month.

Physical + In-Transit Stock Tab (Inventory Position)

This tab measures the inventory position by summing the inventory located at the warehouse and the in-transit inventory. The inventory position is then checked against the reorder point to determine if a new order should be placed for each product.

Volume Reqs – Monthly Orders Tab

This tab calculates the monthly cumulative volume of the products in the warehouse. It does this by importing the individual product volume from the “Product Details” tab and multiplying this number by physical inventory in the “Physical Stock – Monthly Orders” tab. Since the physical inventory in our model is negative during stockouts, the volume equation is set up so that the volume cannot be lower than zero.

The top portion of the tab includes the monthly volumes for each product. At the bottom are the total monthly volumes for each month along with summary statistics on average, maximum and minimum volume requirements. Below the monthly totals on the spreadsheet are data regarding storage capacity at the warehouse.

The storage location for that month's volume is shown. Per review of consumption by site data over the past six months, it was determined that approximately 15.6% of goods were used in the Cange Sociomedical Complex, while the remainder went to regional sites. The warehouse is arranged such that goods remaining in the Cange complex are stored on the shelves, while goods that will be shipped to regional sites are placed on the floor. Therefore, the volume of goods for shelf storage is approximately 15.6% of the total volume. The remaining goods are stored on the floor. Based on the available storage volume on the shelves and floor, it is then calculated whether there is sufficient storage on the shelving and the floor. Instances in which insufficient space is available are shown as a bold "NO".

It should be noted that products for which there is no individual volume data are not included in the cumulative volume requirements. Therefore the number presented in this model should be viewed as an underestimate of true storage requirements.

Volume Reqs – Annual Orders Tab

This tab is similar to the "Volume Reqs – Model Orders" tab but displays cumulative volume data under an annual order system. Due to the larger quantities associated with annual orders, we expect this inventory policy to require greater storage capacity, particularly towards the beginning of the year. Figures 16 and 17 below reveal that the discrepancy between inventory volumes in a monthly order system versus an annual order system is greatest at the beginning of

the year. Additionally, the figures show that model does not include data for the HIV drug Abacavir since we do not have individual volumes for this product.

| Type | Product | 2/28/2010 | 3/31/2010 | 4/30/2010 | 5/31/2010 | 6/30/2010 | 7/31/2010 | 8/31/2010 | 9/30/2010 | 10/31/2010 | 11/30/2010 | 12/31/2010 | 1/31/2011 |
|---------|------------------------------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|------------|------------|------------|-----------|
| EyeCare | Gentamycineeyedrops0.3%10mlOther | 0.085433 | 0.073534 | 0.05049 | 0.031793 | 0.018603 | 0.010581 | 0.007601 | 0.028755 | 0.0407555 | 0.0422736 | 0.0573553 | 0.065005 |
| EyeCare | TetracyclineHydrochloride1%5gOther | 0.089494 | 0.080492 | 0.06282 | 0.045536 | 0.028812 | 0.035266 | 0.030326 | 0.032128 | 0.0371577 | 0.0492222 | 0.0434362 | 0.052261 |
| EyeCare | Timololeyedrops0.25%10mlOther | 0.007564 | 0.006932 | 0.004811 | 0.002062 | 0.002062 | 0.000571 | 0.001104 | 0.002903 | 0.0052935 | 0.0050349 | 0.005083 | 0.005083 |
| HIV | Abacavir300mgTablet | | | | | | | | | | | | |

Figure 16: Product Volume under a Monthly Order System

| Type | Product | 2/28/2010 | 3/31/2010 | 4/30/2010 | 5/31/2010 | 6/30/2010 | 7/31/2010 | 8/31/2010 | 9/30/2010 | 10/31/2010 | 11/30/2010 | 12/31/2010 | 1/31/2011 |
|---------|------------------------------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|------------|------------|------------|-----------|
| EyeCare | Gentamycineeyedrops0.3%10mlOther | 0.164275 | 0.152376 | 0.129332 | 0.110635 | 0.097445 | 0.071424 | 0.056443 | 0.053598 | 0.0535978 | 0.0491159 | 0.0461976 | 0.09923 |
| EyeCare | TetracyclineHydrochloride1%5gOther | 0.207217 | 0.198215 | 0.180543 | 0.163259 | 0.146536 | 0.144065 | 0.127972 | 0.107466 | 0.0901882 | 0.079945 | 0.0674667 | 0.160053 |
| EyeCare | Timololeyedrops0.25%10mlOther | 0.015165 | 0.014533 | 0.012412 | 0.009663 | 0.009663 | 0.007192 | 0.006704 | 0.006004 | 0.0056741 | 0.0054156 | 0.0040237 | 0.010519 |
| HIV | Abacavir300mgTablet | | | | | | | | | | | | |

Figure 17: Product Volume under an Annual Order System

Emergency Procurement Sims Tab

The monthly emergency procurement costs for each simulation iteration are placed in this tab. For each iteration, costs are calculated automatically by the “Simulations” macro for the seven inventory policy scenarios listed in section 4.3. Since 250 iterations were run, each inventory policy has 250 lines of data.

Volume Sims Tab

The inventory volumes in the warehouse from each simulation iteration are placed in this tab. For each iteration, the volume is calculated automatically by the “Simulations” macro for the seven inventory policies.

Container Arrival Sims Tab

The number of arriving containers from each simulation iteration is placed in this tab. For each iteration, the number of containers is calculated automatically by the “Simulations” macro for the seven inventory policies.

Charts Tab

The “Charts” tab provides summary statistics from the “Emergency Procurement Sims”, “Volume Sims” and “Container Arrival Sims” tabs. For these outputs, the mean, fifth percentile and 95th percentile are automatically calculated under each inventory policy. The tab also contains charts illustrating the simulation results for these outputs from 2010 through 2012.

Cange Warehouse Tab

This tab allows for the user to enter the length of the Cange warehouse walls. The output is the total area of the warehouse.

Shelf Storage Tab

This tab allows for entry of shelving length, depth, average aisle width, number of (each variation) of shelves and the number of rows of shelves. The tab also allows the user to alter height between shelves, the number of shelves holding boxes, the number of shelves holding loose goods, and the approximate volume cube used on each shelf. The outputs are total area required for the shelving footprint, and total available volume of the shelving units.

Available Floor Space Tab

This tab allows for input of the exterior aisle width, entry length and width, back aisle width and length, AC units length and width, and the maximum box stacking height. The outputs are the total footprint area available on the warehouse floor, and the total available volume of

goods that can be stacked on the warehouse floor. The total maximum available storage volume in the warehouse (shelf storage plus floor storage) is also an output.

% Goods Cange Tab

This tab calculates the percentage of goods that remain at the Cange Sociomedical complex based on historical consumption data. We used the six month period from July 2009 to December 2009 as the relevant historical period when calculating the percentage of goods that remain in Cange. An alternative historical window could be chosen, if desired.

5.3 Data Analysis Concerns: Missing Product Volumes

As mentioned previously, volume data for approximately one-third of PIH's products was unavailable. This makes evaluation of inventory policies in relation to the available storage volume in the central warehouse difficult.

5.4 Storage Capabilities of the Central Warehouse


The building that houses the central warehouse in Cange consists of two floors (Figure 18). The lower level is used to store equipment, while the upper level contains both office space and storage space. The storage area on this upper level is used to store the products discussed in this thesis. A site visit and subsequent measurements of the upper level found the area to be approximately 185 square meters. This 185 square meters includes a 24 square meter section of the warehouse devoted to cold stores. Therefore, total floor space available for general storage was limited to approximately 161 square meters (See Figure 19).

Storage in the warehouse is split between shelving and the floor. A portion of the goods is stored on plastic shelving. These are goods that will stay on site at the Cange Sociomedical Complex facility. The remaining goods are stored in their original shipping boxes on the warehouse floor. Per review of the last six months of consumption data in 2009, about 15.6% of goods were used within the Cange Sociomedical Complex, and the rest were distributed to regional sites.



Figure 18: Central Warehouse (Cange)

Source: PIH Picasa Web Albums-ZL



AREA=161.4 sq m (EXCLUDING COLD STORES)

Figure 19: Central Warehouse Floor Plan

Shelving Units

Shelving units consist of three or four shelves (Figure 20). The shelves are approximately 0.61 meters (2 feet) deep, with 0.61 meters height between shelves. Each of the shelf units is placed back to back with another shelf unit, resulting in a total shelf depth of 1.22 m (4 feet). There are two shelf lengths used: 1.68 meters (66 inches) and 2.44 meters (96 inches). A total of fourteen 1.68 meter length shelves and eight 2.44 meter length shelves are used in the warehouse. The lowest shelf is used to store boxes of products. The two (three shelf units) or three (four shelf units) upper shelves are used to store loose items.



Figure 20: Shelving in the Central Warehouse

Source: PIH Picsa Web Albums-ZL

Shelving Footprint

There are two components to consider for the shelving footprint: the footprint of the shelves themselves and the footprint of the aisles running between parallel shelves. The footprint

of the shelving in the central warehouse consumes approximately 26 square meters. The footprint of the aisle between the shelves adds approximately 11 square meters. Therefore, the total footprint consumed by the shelving and interior aisles is approximately 37 square meters (Figure 21).




Figure 21: Shelving Footprint, including interior aisles (all dimensions in meters)

Perimeter Aisle Footprint

The footprint of the 0.86 meter (34 inch) aisle that surrounds the perimeter of the shelving is approximately 27 square meters.

Shelving Available Volume

For the purpose of this thesis, we assumed that the utilization of cube on the box storing shelves (lowest shelf on each unit) was 80%. This means that 80% of the volumetric space between the lowest shelf and the shelf above it is used. For the upper shelves that store loose goods, we assumed that the utilization of cube was 20%. We assumed such a low utilization of cube for these shelves as when loose goods are stored at the individual level, they are often small, and use only a small portion of the available volume between shelves. Based on these assumptions, a total of approximately 32.6 cubic meters is available for storage on the shelving units.

Shelving Issues

Staff at PIH Boston considers the current shelving system to be less than optimal. The shelving is plastic, with each shelf consisting of a plastic grid. The opening in the grid pattern is considerable, and causes loose bottles to sit unevenly. Very small bottles can fall through the grid unless cardboard or a similar object is laid on the grid first. The shelf height is not flexible, and therefore cannot be adjusted to suit the storage of the particular items on that shelf.

Floor storage

The remainder, and majority, of goods are stored on the floor of the warehouse, in the original shipping packages (Figure 22). Most of the goods are stored along the walls of the warehouse, two boxes deep. If an additional row or two of boxes is desired beyond two deep, an aisle is formed. The average aisle width between boxes is 0.61 meters (24 inches). To determine the (maximum) amount of available floor storage space, the following method was used:

Area of warehouse - (area of shelving including aisles) - area of air conditioning unit footprint - area of entryway - area of back aisle

The area described as “back aisle” refers to theoretical 0.86m wide aisle that would run the length of the back wall of the warehouse. It represents what would be considered the minimal amount of aisle spacing needed in order to have adequate access to stacked rows of boxes.

We assumed for the model that boxes were stacked 2.44 meters (8 feet) high. Even with these generous assumptions for use of floor storage space, it was determined that only 200 cubic meters of goods can be stored on the floor.



Figure 22: Floor Storage in the Central Warehouse
Source: PIH Picasa Web Albums-ZL

5.5 The St. Marc Warehouse

A new warehouse (Figures 23, 24) has recently been constructed at the St. Marc hospital and clinic in the Artibonite region. At approximately 282 square meters (Figure 11), it is the largest PIH warehouse in Haiti. While the warehouse is already being used for storage, shelving has yet to be installed. Currently, the warehouse only serves its operations in St. Marc. However, due to its large size, the warehouse has potential to serve other areas in the Artibonite region.



Figure 23: Exterior of the St. Marc Warehouse (during construction)

Source: PIH Picasa Web Albums-ZL



Figure 24: Interior of the St. Marc warehouse (during construction)
Source: PIH Picasa Web Albums-ZL




Figure 25: St. Marc Warehouse Layout

6 Results

We ran 250 simulations for each of the five scenarios covered in the Methods section of the paper. Below are the results by metric.

Warehouse Inventory Volume

A review period of one month produces the smallest inventory volume in the warehouse. Furthermore, the inventory volume of all policies from R=1 to R=6 is significantly lower than the volume resulting from an annual order system. A decrease in L from four to two also reduces inventory volume, but the change is relatively small. For example when R=3, a reduction in lead time from four to two months causes inventory volume to decrease 16%. On the other hand changing from annual to quarterly orders reduces inventory volume 56% when L=4. Table 7 details the average inventory volume under different inventory policies.

The first chart (Figure 26) illustrates the monthly volume associated with each inventory policy under one simulation iteration. The second chart (Figure 27) graphs the quantity of amoxicillin contained in the warehouse over time for each inventory policy. The final chart (Figure 28) shows the mean, 5th percentile and 95th percentile of monthly inventory volumes from the 250 simulation iterations when L=4 and R=3. As this chart shows, the range of inventory volumes is narrow in a given month. This finding held for each of the inventory policies.

Table 7: Average Inventory Volume by Policy from 250 Simulations

| <u>Policy</u> | <u>Average Volume</u> | <u>Min Volume</u> | <u>5% Volume</u> | <u>95% Volume</u> | <u>Max Volume</u> |
|---------------|-----------------------|-------------------|------------------|-------------------|-------------------|
| L=2,R=1 | 62 | 36 | 47 | 97 | 160 |
| L=2,R=3 | 125 | 43 | 62 | 201 | 264 |
| L=2,R=6 | 222 | 51 | 81 | 360 | 398 |
| L=4,R=1 | 85 | 42 | 59 | 201 | 264 |
| L=4,R=3 | 147 | 50 | 72 | 292 | 355 |
| L=4,R=6 | 235 | 59 | 88 | 417 | 480 |
| Annual | 339 | 66 | 102 | 610 | 673 |




Figure 26: Warehouse Inventory Volumes by Inventory Policy




Figure 27: Quantity of Amoxicillin by Inventory Policy




Figure 28: Warehouse Inventory Volume with Confidence Bands

Emergency Procurement Costs

In our model emergency procurement costs, are summed over the three years of the simulation and are volatile over the 250 simulations. The second column in Table 8 shows the total emergency procurement costs over the three year forecasted period for each inventory policy. The remaining columns show the summary statistics for monthly emergency procurement costs. The first chart (Figure 29) shows the monthly emergency procurement costs from one iteration for each inventory policy. Generally, an increase in R leads to a reduction in emergency procurement costs. However, there is a tradeoff between emergency procurement costs and inventory volume (Figure 30). The final chart (Figure 31), which shows the mean, 5th percentile and 95th percentile of emergency procurement costs from the 250 simulation iterations, reveals that these costs are much more volatile than inventory volume.

Table 8: Average Emergency Procurement Costs from 250 Simulations

| <u>Policy</u> | <u>Average Total</u> | | <u>5% Total</u> | <u>95% Total</u> | <u>Max Total</u> |
|---------------|--------------------------------|--|--------------------------------|--------------------------------|--------------------------------|
| | <u>Emerg Procurement Costs</u> | <u>Min Total Emerg Procurement Costs</u> | <u>Emerg Procurement Costs</u> | <u>Emerg Procurement Costs</u> | <u>Emerg Procurement Costs</u> |
| L=2,R=1 | \$16,956 | \$8,299 | \$10,662 | \$25,469 | \$36,897 |
| L=2,R=3 | \$11,233 | \$4,170 | \$5,626 | \$19,288 | \$33,979 |
| L=2,R=6 | \$8,647 | \$2,400 | \$3,288 | \$17,513 | \$30,219 |
| L=4,R=1 | \$17,554 | \$7,551 | \$10,277 | \$27,534 | \$42,756 |
| L=4,R=3 | \$12,005 | \$3,986 | \$6,170 | \$20,989 | \$32,794 |
| L=4,R=6 | \$10,809 | \$2,433 | \$4,286 | \$21,450 | \$41,827 |
| Annual | \$11,432 | \$2,454 | \$4,216 | \$21,914 | \$55,028 |




Figure 29: Emergency Procurement Costs by Inventory Policy




Figure 30: Trade-Off Between Inventory Volume and Emergency Procurement Costs




Figure 31: Emergency Procurement Costs with Confidence Bands

Container Arrivals

The number of containers arriving annually is fairly constant across all inventory policies (Table 9). However, the distribution of containers over time is significantly different across inventory policies (Figure 32). The number of containers remains level over time when $R=1$. The curve gets significantly choppier, though, as R increases. Finally, the volatility of the number of containers is minimal across simulations as illustrated in Figure 33.

Table 9: Annual Containers by Inventory Policy

| Policy | Average Annual Containers | Min Annual Containers | 5% Annual Containers | 95% Annual Containers | Max Annual Containers |
|---------|---------------------------|-----------------------|----------------------|-----------------------|-----------------------|
| L=2,R=1 | 9.6 | 9.2 | 9.4 | 9.8 | 10.0 |
| L=2,R=3 | 9.0 | 8.6 | 8.8 | 9.3 | 9.4 |
| L=2,R=6 | 9.5 | 9.1 | 9.2 | 9.7 | 9.8 |
| L=4,R=1 | 9.0 | 8.6 | 8.8 | 9.2 | 9.4 |
| L=4,R=3 | 9.3 | 8.9 | 9.1 | 9.5 | 9.7 |
| L=4,R=6 | 9.4 | 9.0 | 9.2 | 9.6 | 9.7 |
| Annual | 10.7 | 10.4 | 10.5 | 10.9 | 11.1 |




Figure 32: Monthly Containers by Inventory Policy under 1 Simulation




Figure 33: Monthly Incoming Containers with Confidence Bands

7 Additional Factors

7.1 Tracking of Goods

PIH currently performs stock keeping by hand at all sites. Three or four times a year, each site takes a total inventory. A basic barcode system holds the potential to improve the ease and accuracy of stock keeping greatly. The use of Radio Frequency Identification (RFID) tags is another possibility. While RFID tags would provide the least labor intensive way of tracking goods, it might not be practical as it would not allow goods to be tracked at the individual level. In addition, the costs of creating an RFID system are very high.

7.2 January 2010 Earthquake

In January 2010, a 7.0 Mw earthquake struck Haiti outside of Port Au Prince. It is estimated that at least 150,000 lives were lost. Fortunately, neither the Sociomedical Complex nor the regional sites were immediately affected by the quake. However, there will be a permanent increase in the population served by PIH's catchment areas due to internal migration.

It is expected that 500,000 people will move permanently from Port Au Prince. Prior to the earthquake, the city's population was estimated to be between 2.5 and 3 million people. It is expected that a large portion of the population leaving Port au Prince will settle in the Central Plateau. This will affect the number of patients seeking care from PIH's seven Central Plateau sites greatly.

In order to facilitate the movement of goods into Port Au Prince post quake, PIH has rented a large facility in the city. It currently serves as a warehouse for goods and provides PIH with a sense of how an additional large warehouse could help with the flow of goods. PIH is

uncertain whether it will continue renting this facility in the long-term. It has not been ruled out that a facility in Port au Prince could someday serve as an additional centralized warehouse.

Post-earthquake, the plans for the proposed hospital in Mirebalais accelerated quickly from a potential site to a definite site. There is also discussion of constructing a large warehouse at this site. However, at the time of the writing of this thesis, the warehouse construction plans are far from definitive.

7.3 Compounding Issues

Several intangible issues affect the PIH inventory system in Haiti, including hoarding, untimely reporting of stockouts, and political issues. PIH Boston staff considers hoarding to be an issue at the site level. If sites are uncertain if or when they will receive a stock, they will often request more than they actually need as a hedge. Hoarding has long term effects, as it skews the demand figures for that site.

Sites are also guilty of not requesting a good until its inventory is depleted, or has been depleted for some time. Not only does this create an unnecessary emergency order to be generated, but it also skews the reported demand for that product.

Political issues are another source of problems to PIH. Security problems can undermine the safe transportation between sites, and politics often influences the selection of locations for new sites.

8 Recommendations and Conclusion

8.1 Central Warehouse

Even with improved inventory policies, the current size of the second level of the central warehouse is barely large enough to support required storage of goods. One potential area for improvement would be more appropriate shelving. Use of shorter distances between shelves containing smaller items or use of a bin system could allow for additional goods to be stored on the shelves. As stated previously, the use of shelving in the central warehouse is exclusive to those items which will remain for use in the Cange complex. Based on current site usage numbers, limiting shelf usage to only the Cange site does not maximize the amount of goods that could be stored on the shelves. However, with the changes of catchment population the earthquake has brought, this may change.

Another potential area for improvement would be better usage of the lower level of the warehouse. If a portion of the lower level could be used to store the products discussed in this thesis, less aggressive inventory policies could be pursued.

8.2 IDA Order

IDA has made two offers to PIH that would improve stock keeping and stock levels. The first offer was to color code boxes of goods for PIH prior to their shipment to PIH. These color coded boxes could be used to differentiate between categories of products or intended final user (site).

IDA has also offered to decrease lead times on goods if PIH can provide a forecast to IDA with estimated needs prior to their annual order. This “heads up” would allow IDA to obtain

goods before the order is finalized. PIH has been reticent to follow through with this offer, though, as it does not feel confident providing such information.

8.3 Inventory Policies

If PIH were a for-profit company in which processes could be easily changed, we would recommend shifting to a monthly periodic review policy. Ordering products every month results in a much lower inventory volume, while sacrificing less than \$2000 annually in terms of additional emergency procurement costs. Furthermore, the inflow of shipping containers is much more manageable as approximately one container arrives each month, as opposed to ten containers arriving over a three to four months.

However, PIH has indicated that moving to monthly orders may be too onerous for its Haiti staff. Additionally, it is likely that the annual cost of placing and receiving orders would increase with more frequent shipments due to customs and the increased variable cost associated with sending more partially filled containers. Therefore, changing to quarterly or semi-annual review policies would be preferable to annual orders. Doing so will significantly free up warehouse space without causing an increase in emergency procurement costs. Additionally, more frequent shipments will make the warehouse more manageable and allow for easier tracking of PIH's products.

References

- Caplice, C. (2009). *Demand Forecasting I & II Time Series Analysis* [PowerPoint slides]. Retrieved from mit.edu (restricted access).
- Carter, M. W., Golden, B. L. & Wasil, E. A. (2009). Introduction: applications of management science and operations research models and methods to problems in health care. *Interfaces* 39(3), 183-185.
- Hicks, D., Raja, S. & Heinen, F. (2009). *Kenya. Improving Health Systems: Public Sector Healthcare Supply Chain Strategic Network Design for Kemsu*. Retrieved from http://siteresources.worldbank.org/INTHDNETWORK/Resources/Report_Kenya.pdf
- Hicks, D., Purcell, R., Raja, S. & Heinen, F. (2009). *Lesotho. Improving Health Systems: Public Sector Healthcare Supply Chain Strategic Network Analysis and Design*. Retrieved from http://siteresources.worldbank.org/INTHDNETWORK/Resources/Lesotho_supplychain.pdf
- Koenig, S. P., Leandre, F. & Farmer, P. (2004). Scaling-up HIV treatment programs in resource limited settings: the rural Haiti experience. *AIDS* 18(3). S21-S25.
- Levine, R., Pickett, J., Sekhri, N. & Yadav, P. (2008). Demand forecasting for essential medical technologies. *American Journal of Law and Medicine*. 34 (2), 225-255.
- Morreale, D. & Prichard, D. (1995). *Logistics Rules of Thumb, Facts & Definitions III*. Yorba Linda, CA: Council of Logistics Management Southern California Roundtable.
- Silver, E. A., Pyke, D. F., & Peterson, R. (1998). *Inventory Management and Production Planning and Scheduling* (3rd ed.). New York, NY: John Wiley & Sons.
- World Health Organization. (2004). *Management of Drugs at Health Centre Level: Training Manual*. Brazzaville, Africa.

Appendix: Additional Tables and Figures

| Description | #Units | Unit | Quan | Total | | Single | | Unit | | Total | | Volume - | | Annual | | Total | | Price/Qu | | Annual | |
|---|--------|------|------|-----------|------------|------------|----------|------------|-----------|------------|-----------|----------|---------|------------|------------|----------|--------------|----------|--|--------|------|
| | | | | Order | Volume_m3 | Volume_m3 | Order_M3 | Demand_M3 | Weight_KG | Unit | Weight_KG | Unit | Price | Quantity | Total Cost | Demand09 | Demand/Order | | | | |
| Acetazolamide250mgTablet | 6 | 1000 | | 6.000 | 0.00000167 | 0.00166667 | 0.01 | 0.00166667 | 0.01 | 0.00166667 | 4.5 | 20.03 | 0.02003 | 120.18 | | | | | | | |
| Acetylsalicylicacid500mgTablet | 650 | 1000 | | 650.000 | 0.00000062 | 0.00061538 | 0.40 | 0.00061538 | 0.40 | 0.00061538 | 117 | 1.95 | 0.00195 | 1,267.50 | 4.820 | | | | | | 1% |
| Acyclovir200mgTablet | 300 | 500 | | 150.000 | 0.00000100 | 0.0005 | 0.15 | 0.0005 | 0.15 | 0.0005 | 150 | 12.49 | 0.02498 | 3,747.00 | 45.694 | | | | | | 30% |
| Amnophylline25mg/ml10mlAmpulle | 50 | 100 | | 5.000 | 0.00005600 | 0.0056 | 0.28 | 0.0056 | 0.28 | 0.0056 | 97.4 | 44.17 | 0.4417 | 2,208.50 | 792 | | | | | | 16% |
| Amoxicillin125mgBottle | 1325 | 40 | | 53.000 | 0.00042151 | 0.01686038 | 22.34 | 0.01686038 | 22.34 | 0.01686038 | 9010 | 19.33 | 0.48325 | 25,612.25 | | | | | | | |
| Amoxicillin500mgTablet | 3700 | 1000 | | 3,700.000 | 0.00000256 | 0.00255946 | 9.47 | 0.00255946 | 9.47 | 0.00255946 | 3182 | 33.6 | 0.0336 | 124,320.00 | 1,918.142 | | | | | | 52% |
| Amoxicillin/Acicla200/28.5228.5mgTablet | 1000 | 50 | | 50.000 | 0.00001560 | 0.00078 | 0.78 | 0.00078 | 0.78 | 0.00078 | 125 | 8.72 | 0.1744 | 8,720.00 | | | | | | | |
| AmphotericineB50mgAmpulle | 150 | 1 | | 150.000 | 0.00006667 | 6.6667E-05 | 0.01 | 6.6667E-05 | 0.01 | 6.6667E-05 | 3 | 11.51 | 11.51 | 1,726.50 | | | | | | | |
| Ampicillin1gOther | 1500 | 50 | | 75.000 | 0.00005573 | 0.00278667 | 4.18 | 0.00278667 | 4.18 | 0.00278667 | 2115 | 12.35 | 0.247 | 18,525.00 | 37.813 | | | | | | 50% |
| Atenolol50mgTablet | 350 | 1000 | | 350.000 | 0.00000066 | 0.00065714 | 0.23 | 0.00065714 | 0.23 | 0.00065714 | 70 | 6.42 | 0.00642 | 2,247.00 | 91.529 | | | | | | 26% |
| PenicillinBenzathine2.4MIUAmpulle | 550 | 50 | | 27.500 | 0.00005527 | 0.00276364 | 1.52 | 0.00276364 | 1.52 | 0.00276364 | 676.5 | 43.06 | 0.8612 | 23,683.00 | 5.056 | | | | | | 18% |
| Acidbenzoic6%+Acidsalicylic3%40mgOther | 350 | 10 | | 3.500 | 0.00021714 | 0.00217143 | 0.76 | 0.00217143 | 0.76 | 0.00217143 | 218.8 | 4.05 | 0.405 | 1,417.50 | 887 | | | | | | 25% |
| BenzylPenicillin5MIUAmpulle | 100 | 50 | | 5.000 | 0.00008600 | 0.0043 | 0.43 | 0.0043 | 0.43 | 0.0043 | 206 | 43.34 | 0.8668 | 4,334.00 | | | | | | | |
| CalciumGlucanate10%1(ferm)Ampulle | 50 | 20 | | 1.000 | 0.00005000 | 0.001 | 0.05 | 0.001 | 0.05 | 0.001 | 16.5 | 4.26 | 0.213 | 213.00 | | | | | | | |
| Captopril25mgTablet | 2000 | 100 | | 200.000 | 0.00000120 | 0.00012 | 0.24 | 0.00012 | 0.24 | 0.00012 | 70 | 1.26 | 0.0126 | 2,520.00 | 557.240 | | | | | | 279% |
| Carbamazepine200mgTablet | 250 | 1000 | | 250.000 | 0.00000120 | 0.0012 | 0.30 | 0.0012 | 0.30 | 0.0012 | 72.5 | 13.82 | 0.01382 | 3,455.00 | 82.000 | | | | | | 33% |
| Cephalexine500mgTablet | 700 | 100 | | 70.000 | 0.00000243 | 0.00024286 | 0.17 | 0.00024286 | 0.17 | 0.00024286 | 98 | 10.68 | 0.1068 | 7,476.00 | 43.009 | | | | | | 61% |

Figure A1: Product Details Tab

| Type | Product | Feb-10 | Mar-10 | Apr-10 | May-10 | Jun-10 | Jul-10 | Aug-10 |
|---------|--|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| EyeCare | Gentamycineeyedrops0.3%10mlOther | 2.663 | 2.615 | 2.546 | 2.468 | 2.363 | 2.259 | 2.207 |
| EyeCare | TetracyclineHydrochloride1%5gOther | 3.857 | 3.972 | 4.006 | 3.957 | 3.873 | 3.826 | 3.871 |
| EyeCare | Timololeyedrops0.25%10mlOther | 607 | 594 | 583 | 576 | 569 | 550 | 523 |
| HIV | Abacavir300mgTablet | 7.887 | 7.712 | 7.455 | 7.337 | 7.368 | 7.704 | 8.339 |
| HIV | AZT+3TC300/1501tabTablet | 1,319.751 | 1,316.952 | 1,319.746 | 1,328.837 | 1,337.826 | 1,352.964 | 1,371.495 |
| HIV | Didanosine200mgTablet | 893 | 902 | 923 | 936 | 942 | 922 | 888 |
| HIV | Efavirenz200mgTablet | 104.997 | 103.308 | 102.608 | 103.304 | 104.456 | 104.564 | 102.692 |
| HIV | Efavirenz600mgTablet | 486.545 | 487.788 | 488.935 | 488.963 | 488.710 | 491.811 | 500.794 |
| HIV | Indinavir400mgTablet | 50.470 | 50.530 | 50.555 | 50.617 | 50.658 | 50.369 | 50.069 |
| HIV | Lamivudine150mgTablet | 1,164.412 | 1,178.370 | 1,199.676 | 1,218.840 | 1,230.565 | 1,238.743 | 1,253.781 |
| HIV | LamivudineSuspension10mg/10ml240mlBottle | 967 | 940 | 930 | 942 | 969 | 1.013 | 1.070 |
| HIV | Lopinavir/Ritonavir250mgTablet | 149.829 | 151.352 | 155.013 | 159.650 | 164.618 | 170.173 | 183.493 |

Figure A2: Reorder Point Tab

| Type | Product | Feb-10 | Mar-10 | Apr-10 | May-10 | Jun-10 | Jul-10 | Aug-10 |
|---------|--|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| EyeCare | Gentamycineeyedrops0.3%10mlOther | 2.663 | 2.615 | 2.546 | 2.468 | 2.363 | 2.259 | 2.207 |
| EyeCare | TetracyclineHydrochloride1%5gOther | 3.857 | 3.972 | 4.006 | 3.957 | 3.873 | 3.826 | 3.871 |
| EyeCare | Timololeyedrops0.25%10mlOther | 607 | 594 | 583 | 576 | 569 | 550 | 523 |
| HIV | Abacavir300mgTablet | 7.887 | 7.712 | 7.455 | 7.337 | 7.368 | 7.704 | 8.339 |
| HIV | AZT+3TC300/1501tabTablet | 1,319.751 | 1,316.952 | 1,319.746 | 1,328.837 | 1,337.826 | 1,352.964 | 1,371.495 |
| HIV | Didanosine200mgTablet | 893 | 902 | 923 | 936 | 942 | 922 | 888 |
| HIV | Efavirenz200mgTablet | 104.997 | 103.308 | 102.608 | 103.304 | 104.456 | 104.564 | 102.692 |
| HIV | Efavirenz600mgTablet | 486.545 | 487.788 | 488.935 | 488.963 | 488.710 | 491.811 | 500.794 |
| HIV | Indinavir400mgTablet | 50.470 | 50.530 | 50.555 | 50.617 | 50.658 | 50.369 | 50.069 |
| HIV | Lamivudine150mgTablet | 1,164.412 | 1,178.370 | 1,199.676 | 1,218.840 | 1,230.565 | 1,238.743 | 1,253.781 |
| HIV | LamivudineSuspension10mg/10ml240mlBottle | 967 | 940 | 930 | 942 | 969 | 1.013 | 1.070 |
| HIV | Lopinavir/Ritonavir250mgTablet | 149.829 | 151.352 | 155.013 | 159.650 | 164.618 | 170.173 | 183.493 |

Figure A3: Order up to Level Tab

| Type | Product | Feb-10 | Mar-10 | Apr-10 | May-10 | Jun-10 | Jul-10 | Aug-10 |
|---------|--------------------------------------|---------|---------|---------|---------|---------|---------|---------|
| EyeCare | Gentamycineeyedrops0.3%10mlOther | 0 | 247 | 325 | 83 | 428 | 559 | 130 |
| EyeCare | TetracyclineHydrochloride1%5gOther | 324 | 108 | 215 | 399 | 323 | 444 | 487 |
| EyeCare | Timololeyedrops0.25%10mlOther | 24 | 0 | 27 | 94 | 69 | 32 | 29 |
| HIV | Abacavir300mgTablet | 753 | 923 | 659 | 1,317 | 1,026 | 450 | 954 |
| HIV | AZT+3TC300/1501tabTablet | 119,027 | 132,932 | 147,225 | 117,568 | 96,835 | 113,655 | 160,269 |
| HIV | Didanosine200mgTablet | 4 | 28 | 0 | 60 | 85 | 68 | 24 |
| HIV | Efavirenz200mgTablet | 0 | 16,090 | 9,003 | 0 | 9,321 | 4,197 | 10,412 |
| HIV | Efavirenz600mgTablet | 36,615 | 47,807 | 47,231 | 48,920 | 41,460 | 59,802 | 43,327 |
| HIV | Indinavir400mgTablet | 4,360 | 4,879 | 5,533 | 4,176 | 4,104 | 5,195 | 5,269 |
| HIV | Lamivudine150mgTablet | 128,718 | 105,105 | 94,158 | 138,527 | 113,059 | 120,967 | 49,756 |
| HIV | LamivudineSuspension10mg/10ml240mlBo | 67 | 78 | 101 | 126 | 125 | 144 | 91 |
| HIV | Lopinavir/Ritonavir250mgTablet | 15,890 | 17,240 | 20,456 | 13,661 | 20,406 | 8,202 | 11,507 |

Figure A4: Demand Amounts on Simulated Demand Tab

| | | | | | | | | |
|---------|--------------------------------------|----------|----------|----------|----------|----------|----------|----------|
| EyeCare | Gentamycineeyedrops0.3%10mlOther | 0.810055 | 0.688397 | 0.809566 | 0.132136 | 0.890704 | 0.990337 | 0.273993 |
| EyeCare | TetracyclineHydrochloride1%5gOther | 0.742197 | 0.208592 | 0.349933 | 0.706638 | 0.505149 | 0.872906 | 0.903942 |
| EyeCare | Timololeyedrops0.25%10mlOther | 0.401011 | 0.061705 | 0.46552 | 0.910274 | 0.730783 | 0.356974 | 0.338519 |
| HIV | Abacavir300mgTablet | 0.938749 | 0.922482 | 0.055993 | 0.988498 | 0.791216 | 0.016922 | 0.935626 |
| HIV | AZT+3TC300/1501tabTablet | 0.738382 | 0.860461 | 0.923943 | 0.390339 | 0.08313 | 0.242009 | 0.940956 |
| HIV | Didanosine200mgTablet | 0.167493 | 0.350607 | 0.062317 | 0.616249 | 0.650636 | 0.420233 | 0.150582 |
| HIV | Efavirenz200mgTablet | 0.189817 | 0.868536 | 0.737999 | 0.253862 | 0.771121 | 0.566682 | 0.764301 |
| HIV | Efavirenz600mgTablet | 0.533664 | 0.847779 | 0.688337 | 0.630272 | 0.25394 | 0.942295 | 0.451039 |
| HIV | Indinavir400mgTablet | 0.509074 | 0.721611 | 0.928435 | 0.415172 | 0.27798 | 0.731457 | 0.800633 |
| HIV | Lamivudine150mgTablet | 0.887957 | 0.61416 | 0.414374 | 0.965592 | 0.673896 | 0.853068 | 0.010689 |
| HIV | LamivudineSuspension10mg/10ml240mlBo | 0.155608 | 0.149753 | 0.3191 | 0.713981 | 0.781603 | 0.984642 | 0.794917 |
| HIV | Lopinavir/Ritonavir250mgTablet | 0.596788 | 0.704034 | 0.907018 | 0.232873 | 0.899978 | 0.493852 | 0.7685 |

Figure A5: Random Numbers at the Bottom of the Simulated Demand Tab

| Type | Product | 2/28/2010 | 3/31/2010 | 4/30/2010 | 5/31/2010 | 6/30/2010 | 7/31/2010 | 8/31/2010 | 9/30/2010 | 10/31/2010 | 11/30/2010 |
|---------|--|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|------------|------------|
| EyeCare | Gentamycineeyedrops0.3%10mlOther | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 109 |
| EyeCare | TetracyclineHydrochloride1%5gOther | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EyeCare | Timololeyedrops0.25%10mlOther | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIV | Abacavir300mgTablet | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIV | AZT+3TC300/1501tabTablet | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIV | Didanosine200mgTablet | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIV | Efavirenz200mgTablet | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIV | Efavirenz600mgTablet | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIV | Indinavir400mgTablet | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIV | Lamivudine150mgTablet | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIV | LamivudineSuspension10mg/10ml240mlBottle | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIV | Lopinavir/Ritonavir250mgTablet | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

Figure A6: Emergency – Monthly Orders Tab

| Type | Product | 2/28/2010 | 3/31/2010 | 4/30/2010 | 5/31/2010 | 6/30/2010 | 7/31/2010 | 8/31/2010 |
|---------|--|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| EyeCare | Gentamycineeyedrops0.3%10mlOther | 2.848 | 2.601 | 2.276 | 2.193 | 1.765 | 1.207 | 1.076 |
| EyeCare | TetracyclineHydrochloride1%5gOther | 3.949 | 3.840 | 3.626 | 3.227 | 2.904 | 2.460 | 1.972 |
| EyeCare | Timololeyedrops0.25%10mlOther | 628 | 628 | 601 | 508 | 439 | 407 | 378 |
| HIV | Abacavir300mgTablet | 7.563 | 6.640 | 5.981 | 4.664 | 3.638 | 3.189 | 2.235 |
| HIV | AZT+3TC300/1501tabTablet | 1.318.285 | 1.185.353 | 1.038.128 | 920.560 | 823.725 | 710.070 | 549.801 |
| HIV | Didanosine200mgTablet | 981 | 953 | 953 | 893 | 808 | 740 | 717 |
| HIV | Efavirenz200mgTablet | 115.471 | 99.381 | 90.379 | 90.379 | 81.057 | 76.860 | 66.448 |
| HIV | Efavirenz600mgTablet | 493.492 | 445.685 | 398.455 | 349.535 | 308.075 | 248.273 | 204.946 |
| HIV | Indinavir400mgTablet | 51.105 | 46.226 | 40.693 | 36.517 | 32.412 | 27.218 | 21.949 |
| HIV | Lamivudine150mgTablet | 1.167.760 | 1.062.655 | 968.497 | 829.970 | 716.911 | 595.943 | 546.187 |
| HIV | LamivudineSuspension10mg/10ml240mlBottle | 977 | 899 | 798 | 672 | 547 | 403 | 312 |
| HIV | Lopinavir/Ritonavir250mgTablet | 152.192 | 134.952 | 114.496 | 100.835 | 80.429 | 72.227 | 60.720 |

Figure A7: Physical Stock – Annual Orders

| Type | Product | 2/28/2010 | 3/31/2010 | 4/30/2010 | 5/31/2010 | 6/30/2010 | 7/31/2010 | 8/31/2010 |
|---------|--|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| EyeCare | Gentamycineeyedrops0.3%10mlOther | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EyeCare | TetracyclineHydrochloride1%5gOther | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EyeCare | Timololeyedrops0.25%10mlOther | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIV | Abacavir300mgTablet | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIV | AZT+3TC300/1501tabTablet | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIV | Didanosine200mgTablet | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIV | Efavirenz200mgTablet | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIV | Efavirenz600mgTablet | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIV | Indinavir400mgTablet | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIV | Lamivudine150mgTablet | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIV | LamivudineSuspension10mg/10ml240mlBottle | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HIV | Lopinavir/Ritonavir250mgTablet | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

Figure A8: Emergency – Annual Orders Tab

| Type | Product | 3/1/2010 | 4/1/2010 | 5/1/2010 | 6/1/2010 | 7/1/2010 | 8/1/2010 | 9/1/2010 | 10/1/2010 | 11/1/2010 | 12/1/2010 |
|---------|--|----------|----------|----------|----------|----------|----------|----------|-----------|-----------|-----------|
| EyeCare | Gentamycineeyedrops0.3%10mlOther | 0 | 0 | 0 | 0 | 0 | 0 | 0.03 | 0 | 0 | 0.042 |
| EyeCare | TetracyclineHydrochloride1%5gOther | 0 | 0 | 0 | 0 | 0 | 0.049077 | 0 | 0 | 0 | 0.046846 |
| EyeCare | Timololeyedrops0.25%10mlOther | 0 | 0 | 0 | 0 | 0 | 0.00096 | 0 | 0 | 0 | 0.00286 |
| HIV | Abacavir300mgTablet | | | | | | | | | | |
| HIV | AZT+3TC300/1501tabTablet | | | | | | | | | | |
| HIV | Didanosine200mgTablet | | | | | | | | | | |
| HIV | Efavirenz200mgTablet | | | | | | | | | | |
| HIV | Efavirenz600mgTablet | | | | | | | | | | |
| HIV | Indinavir400mgTablet | | | | | | | | | | |
| HIV | Lamivudine150mgTablet | | | | | | | | | | |
| HIV | LamivudineSuspension10mg/10ml240mlBottle | | | | | | | | | | |
| HIV | Lopinavir/Ritonavir250mgTablet | | | | | | | | | | |

Figure A9: Container Arrival Tab (no volume data for HIV drugs)

| Type | Product | 3/31/2010 | 4/30/2010 | 5/31/2010 | 6/30/2010 | 7/31/2010 | 8/31/2010 |
|---------|--|-----------|-----------|-----------|-----------|-----------|-----------|
| EyeCare | Gentamycineeyedrops0.3%10mlOther | 0 | 0 | 500 | 500 | 500 | 1.200 |
| EyeCare | TetracyclineHydrochloride1%5gOther | 0 | 0 | 1,100 | 1,100 | 1,100 | 2.150 |
| EyeCare | Timololeyedrops0.25%10mlOther | 0 | 0 | 48 | 48 | 48 | 191 |
| HIV | Abacavir300mgTablet | 0 | 0 | 1,900 | 1,900 | 1,900 | 3.600 |
| HIV | AZT+3TC300/1501tabTablet | 0 | 0 | 394,000 | 394,000 | 394,000 | 689,000 |
| HIV | Didanosine200mgTablet | 0 | 0 | 100 | 100 | 100 | 300 |
| HIV | Efavirenz200mgTablet | 0 | 0 | 21,600 | 21,600 | 21,600 | 38,800 |
| HIV | Efavirenz600mgTablet | 0 | 0 | 133,400 | 133,400 | 133,400 | 264,200 |
| HIV | Indinavir400mgTablet | 0 | 0 | 14,800 | 14,800 | 14,800 | 27,800 |
| HIV | Lamivudine150mgTablet | 0 | 0 | 336,100 | 336,100 | 336,100 | 760,600 |
| HIV | LamivudineSuspension10mg/10ml240mlBottle | 0 | 0 | 100 | 100 | 100 | 500 |
| HIV | Lopinavir/Ritonavir250mgTablet | 0 | 0 | 43,400 | 43,400 | 43,400 | 101,600 |

Figure A10: In-transit Stock Tab

| Type | Product | 2/28/2010 | 3/31/2010 | 4/30/2010 | 5/31/2010 | 6/30/2010 | 7/31/2010 | 8/31/2010 |
|---------|--|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| EyeCare | Gentamycineeyedrops0.3%10mlOther | 2.095 | 1.848 | 1.523 | 1.940 | 1.512 | 954 | 1,524 |
| EyeCare | TetracyclineHydrochloride1%5gOther | 2.268 | 2.160 | 1.945 | 2.646 | 2.323 | 1,879 | 2,442 |
| EyeCare | Timololeyedrops0.25%10mlOther | 447 | 447 | 420 | 374 | 305 | 273 | 387 |
| HIV | Abacavir300mgTablet | 5,401 | 4,477 | 3,818 | 4,401 | 3,375 | 2,926 | 3,672 |
| HIV | AZT+3TC300/1501tabTablet | 846,770 | 713,838 | 566,613 | 843,045 | 746,210 | 632,555 | 767,286 |
| HIV | Didanosine200mgTablet | 645 | 617 | 617 | 658 | 572 | 504 | 681 |
| HIV | Efavirenz200mgTablet | 85,570 | 69,479 | 60,477 | 82,077 | 72,755 | 68,559 | 75,347 |
| HIV | Efavirenz600mgTablet | 320,260 | 272,454 | 225,223 | 309,703 | 268,243 | 208,442 | 295,914 |
| HIV | Indinavir400mgTablet | 32,057 | 27,178 | 21,644 | 32,268 | 28,164 | 22,969 | 30,700 |
| HIV | Lamivudine150mgTablet | 701,408 | 596,303 | 502,145 | 699,718 | 586,659 | 465,691 | 840,435 |
| HIV | LamivudineSuspension10mg/10ml240mlBottle | 728 | 649 | 548 | 523 | 398 | 254 | 563 |
| HIV | Lopinavir/Ritonavir250mgTablet | 94,765 | 77,525 | 57,069 | 86,807 | 66,401 | 58,199 | 104,893 |

Figure A11: Physical + In-transit Stock Tab

| L=2,R=1, S=s | 2/28/2010 | 3/31/2010 | 4/30/2010 | 5/31/2010 | 6/30/2010 | 7/31/2010 | 8/31/2010 |
|--------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| 1 | 0 | 1.529094 | 754.9361 | 1108.68 | 2459.653 | 414.7972 | 436.8792 |
| 2 | 0 | 2.010361 | 951.9289 | 1680.435 | 581.424 | 377.669 | 22.93716 |
| 3 | 0 | 0 | 81.18212 | 87.11694 | 64.49318 | 169.8114 | 426.0513 |
| 4 | 0 | 0 | 145.5624 | 340.5019 | 39.81957 | 20.2967 | 568.9099 |
| 5 | 0 | 0 | 913.9205 | 915.5154 | 76.6351 | 241.9465 | 589.299 |
| 6 | 0 | 0 | 95.20619 | 652.0485 | 449.3989 | 1506.502 | 107.5392 |
| 7 | 0 | 0 | 485.6311 | 129.9745 | 875.6231 | 199.0163 | 181.8347 |
| 8 | 0 | 1.786065 | 1902.317 | 948.7163 | 560.461 | 54.86108 | 337.5746 |
| 9 | 0 | 0 | 129.2144 | 438.4999 | 715.1361 | 308.6196 | 631.2162 |
| 10 | 0 | 22.48213 | 99.81429 | 300.5753 | 88.67926 | 3540.932 | 1696.734 |
| 11 | 0 | 0.942614 | 1427.077 | 1075.555 | 174.6578 | 644.9992 | 76.54977 |
| 12 | 0 | 37.36208 | 216.8549 | 24.54711 | 438.8139 | 135.9448 | 124.1808 |
| 13 | 474.4279 | 3767.885 | 884.3781 | 1066.366 | 622.9787 | 95.81842 | 1056.691 |

Figure A12: Emergency Procurement Sims Tab

| L=2,R=1, S=s | <u>2/28/2010</u> | <u>3/31/2010</u> | <u>4/30/2010</u> | <u>5/31/2010</u> | <u>6/30/2010</u> | <u>7/31/2010</u> | <u>8/31/2010</u> |
|--------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| 1 | 148.8269 | 107.3425 | 62.15246 | 61.60583 | 55.77249 | 59.87705 | 62.79633 |
| 2 | 142.1537 | 89.74997 | 51.81979 | 57.24979 | 64.17462 | 51.63648 | 49.53593 |
| 3 | 153.7051 | 107.2775 | 71.42244 | 62.44629 | 68.00204 | 64.72125 | 72.60621 |
| 4 | 137.9841 | 89.82356 | 42.57616 | 52.34394 | 59.69051 | 61.88461 | 61.25429 |
| 5 | 140.4507 | 96.22331 | 50.82569 | 61.62839 | 61.94106 | 63.15993 | 58.51918 |
| 6 | 151.925 | 108.9685 | 63.24501 | 66.68482 | 61.16927 | 56.45975 | 46.06539 |
| 7 | 139.9142 | 93.56144 | 55.17992 | 64.49739 | 65.45464 | 56.28977 | 52.01657 |
| 8 | 154.7294 | 105.2881 | 56.63884 | 53.0896 | 59.05828 | 69.3456 | 66.00748 |
| 9 | 154.2446 | 101.7647 | 59.00005 | 47.15901 | 54.5327 | 49.34911 | 49.73985 |
| 10 | 149.2292 | 98.27845 | 53.35294 | 51.98968 | 61.18116 | 51.58056 | 56.95356 |
| 11 | 140.04 | 100.2181 | 52.88786 | 58.84486 | 52.25837 | 53.63829 | 57.45345 |
| 12 | 149.8751 | 106.0822 | 61.7072 | 59.86537 | 63.06185 | 65.2194 | 63.63126 |
| 13 | 129.4594 | 87.713 | 44.65695 | 59.04087 | 62.23452 | 55.53812 | 56.28308 |

Figure A13: Volume Sims Tab

| L=2,R=1, S=s | <u>3/1/2010</u> | <u>4/1/2010</u> | <u>5/1/2010</u> | <u>6/1/2010</u> | <u>7/1/2010</u> | <u>8/1/2010</u> | <u>9/1/2010</u> |
|--------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| 1 | 0 | 0 | 0.884954 | 0.814685 | 0.775654 | 0.748671 | 0.904967 |
| 2 | 0 | 0 | 0.897424 | 0.96387 | 0.615473 | 0.794902 | 0.685109 |
| 3 | 0 | 0 | 0.689938 | 0.852325 | 0.577122 | 0.768405 | 0.623926 |
| 4 | 0 | 0 | 0.97681 | 0.882392 | 0.792299 | 0.712467 | 0.630217 |
| 5 | 0 | 0 | 0.931046 | 0.811467 | 0.754297 | 0.641477 | 0.690428 |
| 6 | 0 | 0 | 0.723014 | 0.786295 | 0.764506 | 0.571067 | 0.785166 |
| 7 | 0 | 0 | 0.943488 | 0.846635 | 0.624262 | 0.687698 | 0.712333 |
| 8 | 0 | 0 | 0.675501 | 0.898234 | 0.811194 | 0.657404 | 0.664415 |
| 9 | 0 | 0 | 0.679093 | 0.966292 | 0.705791 | 0.802184 | 0.717143 |
| 10 | 0 | 0 | 0.775757 | 0.930039 | 0.744091 | 0.726779 | 0.627832 |
| 11 | 0 | 0 | 0.938562 | 0.728068 | 0.807414 | 0.726198 | 0.718958 |
| 12 | 0 | 0 | 0.757901 | 0.800544 | 0.741482 | 0.694901 | 0.640594 |
| 13 | 0 | 0 | 1.151512 | 0.892644 | 0.711669 | 0.72485 | 0.678222 |

Figure A14: Container Arrival Tab